WO2018110515A1 - 抗体-薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ - Google Patents
抗体-薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ Download PDFInfo
- Publication number
- WO2018110515A1 WO2018110515A1 PCT/JP2017/044426 JP2017044426W WO2018110515A1 WO 2018110515 A1 WO2018110515 A1 WO 2018110515A1 JP 2017044426 W JP2017044426 W JP 2017044426W WO 2018110515 A1 WO2018110515 A1 WO 2018110515A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- cancer
- drug conjugate
- pharmaceutical composition
- action
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title claims abstract description 445
- 229940049595 antibody-drug conjugate Drugs 0.000 title claims abstract description 445
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title claims abstract description 72
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 title claims abstract description 72
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 title claims abstract description 72
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title claims abstract description 72
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 132
- 238000000034 method Methods 0.000 claims abstract description 107
- 239000003814 drug Substances 0.000 claims abstract description 105
- 229940079593 drug Drugs 0.000 claims abstract description 100
- 230000000694 effects Effects 0.000 claims abstract description 85
- 201000010099 disease Diseases 0.000 claims abstract description 48
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 48
- 230000005809 anti-tumor immunity Effects 0.000 claims abstract description 35
- 230000001668 ameliorated effect Effects 0.000 claims abstract description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 308
- 210000004027 cell Anatomy 0.000 claims description 228
- 230000009471 action Effects 0.000 claims description 168
- 201000011510 cancer Diseases 0.000 claims description 124
- 230000003213 activating effect Effects 0.000 claims description 76
- 210000004443 dendritic cell Anatomy 0.000 claims description 70
- 230000000259 anti-tumor effect Effects 0.000 claims description 69
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 68
- 230000001737 promoting effect Effects 0.000 claims description 67
- 108091007433 antigens Proteins 0.000 claims description 64
- 102000036639 antigens Human genes 0.000 claims description 63
- 239000000427 antigen Substances 0.000 claims description 62
- 150000001875 compounds Chemical class 0.000 claims description 62
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 59
- 230000002601 intratumoral effect Effects 0.000 claims description 47
- 108091054437 MHC class I family Proteins 0.000 claims description 40
- 102000043129 MHC class I family Human genes 0.000 claims description 40
- 206010009944 Colon cancer Diseases 0.000 claims description 34
- 206010006187 Breast cancer Diseases 0.000 claims description 32
- 208000026310 Breast neoplasm Diseases 0.000 claims description 32
- 230000015572 biosynthetic process Effects 0.000 claims description 30
- 230000006054 immunological memory Effects 0.000 claims description 30
- 238000002560 therapeutic procedure Methods 0.000 claims description 30
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 29
- 150000001413 amino acids Chemical class 0.000 claims description 28
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 27
- 238000002360 preparation method Methods 0.000 claims description 22
- 208000029742 colonic neoplasm Diseases 0.000 claims description 21
- 210000001519 tissue Anatomy 0.000 claims description 21
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 20
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 20
- 206010005003 Bladder cancer Diseases 0.000 claims description 19
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 19
- 206010014733 Endometrial cancer Diseases 0.000 claims description 19
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 19
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 19
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 19
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 19
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 19
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 19
- 206010025323 Lymphomas Diseases 0.000 claims description 19
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 19
- 206010027406 Mesothelioma Diseases 0.000 claims description 19
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 19
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 19
- 206010033128 Ovarian cancer Diseases 0.000 claims description 19
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 19
- 208000027868 Paget disease Diseases 0.000 claims description 19
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 19
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 19
- 206010034299 Penile cancer Diseases 0.000 claims description 19
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims description 19
- 206010034811 Pharyngeal cancer Diseases 0.000 claims description 19
- 208000007452 Plasmacytoma Diseases 0.000 claims description 19
- 206010060862 Prostate cancer Diseases 0.000 claims description 19
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 19
- 206010038389 Renal cancer Diseases 0.000 claims description 19
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 19
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 19
- 206010039491 Sarcoma Diseases 0.000 claims description 19
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 19
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 19
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 19
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 19
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 19
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 19
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 19
- 201000010881 cervical cancer Diseases 0.000 claims description 19
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 19
- 201000004101 esophageal cancer Diseases 0.000 claims description 19
- 201000010175 gallbladder cancer Diseases 0.000 claims description 19
- 206010017758 gastric cancer Diseases 0.000 claims description 19
- 201000007492 gastroesophageal junction adenocarcinoma Diseases 0.000 claims description 19
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 19
- 201000010536 head and neck cancer Diseases 0.000 claims description 19
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 19
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 19
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 19
- 201000010982 kidney cancer Diseases 0.000 claims description 19
- 208000032839 leukemia Diseases 0.000 claims description 19
- 201000007270 liver cancer Diseases 0.000 claims description 19
- 208000014018 liver neoplasm Diseases 0.000 claims description 19
- 201000005202 lung cancer Diseases 0.000 claims description 19
- 208000020816 lung neoplasm Diseases 0.000 claims description 19
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 19
- 208000027202 mammary Paget disease Diseases 0.000 claims description 19
- 201000002528 pancreatic cancer Diseases 0.000 claims description 19
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 19
- 201000002628 peritoneum cancer Diseases 0.000 claims description 19
- 201000000849 skin cancer Diseases 0.000 claims description 19
- 201000011549 stomach cancer Diseases 0.000 claims description 19
- 201000002510 thyroid cancer Diseases 0.000 claims description 19
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 19
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 19
- 206010046766 uterine cancer Diseases 0.000 claims description 19
- 201000005102 vulva cancer Diseases 0.000 claims description 19
- 208000023833 nerve sheath neoplasm Diseases 0.000 claims description 18
- 206010004593 Bile duct cancer Diseases 0.000 claims description 17
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 17
- 239000004480 active ingredient Substances 0.000 claims description 15
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 13
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 13
- 230000001506 immunosuppresive effect Effects 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 201000005528 peripheral nervous system neoplasm Diseases 0.000 claims description 9
- 210000000981 epithelium Anatomy 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 4
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 230000004913 activation Effects 0.000 abstract description 4
- 241000699670 Mus sp. Species 0.000 description 74
- 125000005647 linker group Chemical group 0.000 description 52
- 238000011156 evaluation Methods 0.000 description 39
- 238000012360 testing method Methods 0.000 description 28
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 25
- 238000000684 flow cytometry Methods 0.000 description 25
- 235000001014 amino acid Nutrition 0.000 description 20
- 239000003795 chemical substances by application Substances 0.000 description 19
- 230000001965 increasing effect Effects 0.000 description 17
- 238000004519 manufacturing process Methods 0.000 description 17
- 210000003462 vein Anatomy 0.000 description 17
- 241000282414 Homo sapiens Species 0.000 description 15
- 210000004989 spleen cell Anatomy 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 10
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 9
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 8
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 102000001398 Granzyme Human genes 0.000 description 7
- 108060005986 Granzyme Proteins 0.000 description 7
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 7
- 230000028993 immune response Effects 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 6
- 102100027212 Tumor-associated calcium signal transducer 2 Human genes 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 102000051957 human ERBB2 Human genes 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 125000003396 thiol group Chemical group [H]S* 0.000 description 6
- 108091054438 MHC class II family Proteins 0.000 description 5
- 102000043131 MHC class II family Human genes 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 239000012830 cancer therapeutic Substances 0.000 description 5
- 238000011580 nude mouse model Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 229960000575 trastuzumab Drugs 0.000 description 5
- 206010015548 Euthanasia Diseases 0.000 description 4
- 102100022297 Integrin alpha-X Human genes 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 210000001099 axilla Anatomy 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 239000000890 drug combination Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 229960001612 trastuzumab emtansine Drugs 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 101150029707 ERBB2 gene Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 3
- 101150117918 Tacstd2 gene Proteins 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000000981 bystander Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000002301 combined effect Effects 0.000 description 3
- 239000000562 conjugate Substances 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- ZVYVPGLRVWUPMP-FYSMJZIKSA-N exatecan Chemical compound C1C[C@H](N)C2=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC3=CC(F)=C(C)C1=C32 ZVYVPGLRVWUPMP-FYSMJZIKSA-N 0.000 description 3
- 229950009429 exatecan Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000001325 log-rank test Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229950010966 patritumab Drugs 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- -1 2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl Chemical group 0.000 description 2
- PBVAJRFEEOIAGW-UHFFFAOYSA-N 3-[bis(2-carboxyethyl)phosphanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)CCP(CCC(O)=O)CCC(O)=O PBVAJRFEEOIAGW-UHFFFAOYSA-N 0.000 description 2
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 2
- 238000001061 Dunnett's test Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 2
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 229960003852 atezolizumab Drugs 0.000 description 2
- 229950002916 avelumab Drugs 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 210000001728 clone cell Anatomy 0.000 description 2
- 238000004163 cytometry Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229950009791 durvalumab Drugs 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000002637 immunotoxin Effects 0.000 description 2
- 239000002596 immunotoxin Substances 0.000 description 2
- 229940051026 immunotoxin Drugs 0.000 description 2
- 231100000608 immunotoxin Toxicity 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- 229960004891 lapatinib Drugs 0.000 description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 2
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
- 229960004338 leuprorelin Drugs 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- 229960002087 pertuzumab Drugs 0.000 description 2
- 238000001050 pharmacotherapy Methods 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229950008834 seribantumab Drugs 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 229950007217 tremelimumab Drugs 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101001009603 Homo sapiens Granzyme B Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000746372 Mus musculus Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101001009604 Mus musculus Granzyme B(G,H) Proteins 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 108700012457 TACSTD2 Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000007801 affinity label Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000002494 anti-cea effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008716 dendritic activation Effects 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229950002519 elgemtumab Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229960004750 estramustine phosphate Drugs 0.000 description 1
- ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 238000013388 immunohistochemistry analysis Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229950010079 lumretuzumab Drugs 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000009099 neoadjuvant therapy Methods 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 208000027831 neuroepithelial neoplasm Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention includes a pharmaceutical composition and a therapeutic method, and a specific antibody-drug conjugate, characterized in that the specific antibody-drug conjugate and the immune checkpoint inhibitor are administered in combination.
- the present invention also relates to a pharmaceutical composition and a therapeutic method characterized by being used for the treatment of a disease that is improved by an action of activating antitumor immunity.
- ADC Antibody-drug conjugate
- a cytotoxic drug is bound to an antibody that binds to an antigen that is expressed on the surface of a cancer cell and can be internalized in the cell, is selected for cancer cells Therefore, it can be expected that the drug can be delivered to the cancer cell and the cancer cell is killed (Non-Patent Documents 1 to 5).
- antibody-drug conjugates comprising an antibody and exatecan, which is a topoisomerase I inhibitor
- Patent Documents 1 to 7 As one of antibody-drug conjugates, antibody-drug conjugates comprising an antibody and exatecan, which is a topoisomerase I inhibitor, are known (Patent Documents 1 to 7). Among these, clinical trials are currently in progress for anti-HER2 antibody-drug conjugates (Non-Patent Documents 6 and 7) having particularly excellent antitumor effects and safety.
- An immune checkpoint inhibitor is a drug that inhibits the immune suppression system and activates anti-tumor immunity (Non-Patent Documents 8 to 10).
- anti-PD-1 antibodies such as nivolumab (patent document 8), pembrolizumab (patent document 9), and anti-PD-L1 antibody, atezolizumab (patent) Reference 10), Durvalumab (patent document 11), Avelumab (patent document 12), anti-CTLA-4 antibody, ipilimumab (patent document 13), tremelimumab (patent document 14) ), Etc. are known.
- An object of the present invention is to provide a pharmaceutical composition and a therapeutic method having an excellent antitumor effect and safety by administering an antibody-drug conjugate and an immune checkpoint inhibitor in combination.
- the present invention provides a pharmaceutical composition and a treatment method comprising a specific antibody-drug conjugate, which is used for the treatment of a disease that is ameliorated by an effect of activating antitumor immunity. It is a problem.
- the present inventors have found that a specific antibody-drug conjugate and an immune checkpoint inhibitor are administered in combination to exhibit an excellent antitumor effect. Further, the present inventors have found that the antibody-drug conjugate has an effect of activating antitumor immunity.
- a pharmaceutical composition characterized in that an antibody-drug conjugate and an immune checkpoint inhibitor are administered in combination comprising:
- the antibody-drug conjugate has the formula
- a pharmaceutical composition which is an antibody-drug conjugate in which a drug linker represented by the above and an antibody are bound by a thioether bond.
- the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence described in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence described in amino acid numbers 1 to 214 in SEQ ID NO: 2.
- the pharmaceutical composition according to [9], wherein the immune checkpoint inhibitor is an anti-PD-1 antibody.
- the pharmaceutical composition according to [9], wherein the immune checkpoint inhibitor is an anti-PD-L1 antibody.
- the pharmaceutical composition according to [9], wherein the immune checkpoint inhibitor is an anti-CTLA-4 antibody.
- Any one of [1] to [12], wherein the antibody-drug conjugate and the immune checkpoint inhibitor are contained in different preparations as active ingredients, and are administered simultaneously or at different times 2.
- the medicament according to any one of [1] to [12], wherein the antibody-drug conjugate and the immune checkpoint inhibitor are contained as an active ingredient and administered in a single preparation. Composition.
- Cancer is lung cancer, urothelial cancer, colon cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, gastroesophageal junction adenocarcinoma, gastrointestinal stromal tumor, cervical cancer, esophageal cancer, squamous epithelium Cancer, peritoneal cancer, liver cancer, hepatocellular carcinoma, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulva cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, neuroepithelium [15] at least one selected from the group consisting of tissue tumor, nerve sheath tumor, head and neck cancer, skin cancer, pharyngeal cancer, gallbladder cancer, bile duct cancer, mesothelioma, Paget's disease, and sar
- the antibody-drug conjugate is (1) the action of promoting the increase of intratumoral CD8 positive T cells, and (2) an effect of activating intratumoral CD8 positive T cells,
- the antibody-drug conjugate is (1) an action that promotes an increase in the number of dendritic cells in the tumor; (2) the action of activating dendritic cells, and (3) an action that promotes an increase in the expression level of MHC class I on cancer cells;
- the antibody-drug conjugate releases the immunosuppressive signal generated by promoting the increase in the expression level of PD-L1 on the cancer cell by the immune checkpoint inhibitor.
- the pharmaceutical composition according to any one of [1] to [24] which exhibits a stronger antitumor effect. [26] formula
- a pharmaceutical composition comprising an antibody-drug conjugate in which a drug linker represented by the above is bound to an antibody by a thioether bond, and used for the treatment of a disease that is ameliorated by an effect of activating antitumor immunity.
- the antibody-drug conjugate is (1) the action of promoting the increase of intratumoral CD8 positive T cells, and (2) an effect of activating intratumoral CD8 positive T cells,
- the pharmaceutical composition according to [26] which has at least one action selected from the group consisting of: [28] [26] or [27]
- the pharmaceutical composition according to [26] or [27] wherein the antibody-drug conjugate has an effect of promoting formation of an immune memory against a tumor.
- the antibody-drug conjugate is (1) an action that promotes an increase in the number of dendritic cells in the tumor; (2) the action of activating dendritic cells, and (3) an action that promotes an increase in the expression level of MHC class I on cancer cells;
- the pharmaceutical composition according to [32] wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.
- the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence described in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence described in amino acid numbers 1 to 214 in SEQ ID NO: 2. [32] or the pharmaceutical composition according to [33]. [35] The pharmaceutical composition according to [32] or [33], wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2. object.
- [39] Disease is lung cancer, urothelial cancer, colon cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, gastroesophageal junction adenocarcinoma, gastrointestinal stromal tumor, cervical cancer, esophageal cancer, squamous cell carcinoma , Peritoneal cancer, liver cancer, hepatocellular carcinoma, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulva cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, neuroepithelial tissue At least one selected from the group consisting of sex tumors, nerve sheath tumors, head and neck cancer, skin cancer, pharyngeal cancer, gallbladder cancer, bile duct cancer, mesothelioma, Paget's disease, and sarcoma [26] To [38].
- the pharmaceutical composition according to any one of [38]. [
- composition characterized by using in the treatment of the disease improved with the effect
- Compound is (1) the action of promoting the increase of intratumoral CD8 positive T cells, and (2) an effect of activating intratumoral CD8 positive T cells,
- Compound is (1) an action that promotes an increase in the number of dendritic cells in the tumor; (2) the action of activating dendritic cells, and (3) an action that promotes an increase in the expression level of MHC class I on cancer cells;
- a therapeutic method which is an antibody-drug conjugate in which a drug linker represented by the above and an antibody are bound by a thioether bond.
- the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence described in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence described in amino acid numbers 1 to 214 in SEQ ID NO: 2.
- Cancer is lung cancer, urothelial cancer, colon cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, gastroesophageal junction adenocarcinoma, gastrointestinal stromal tumor, cervical cancer, esophageal cancer, squamous epithelium Cancer, peritoneal cancer, liver cancer, hepatocellular carcinoma, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulva cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, neuroepithelium [61] at least one selected from the group consisting of tissue tumors, nerve sheath tumors, head and neck cancer, skin cancer, pharyngeal cancer, gallbladder cancer, bile duct cancer, mesothelioma, Paget's disease, and
- the antibody-drug conjugate is (1) the action of promoting the increase of intratumoral CD8 positive T cells, and (2) an effect of activating intratumoral CD8 positive T cells,
- the antibody-drug conjugate is (1) an action that promotes an increase in the number of dendritic cells in the tumor; (2) the action of activating dendritic cells, and (3) an action that promotes an increase in the expression level of MHC class I on cancer cells;
- the antibody-drug conjugate releases the immunosuppressive signal generated by promoting the increase in the expression level of PD-L1 on the cancer cell by the immune checkpoint inhibitor.
- the treatment method according to any one of [47] to [70] which exhibits a stronger antitumor effect.
- a therapeutic method comprising administering an antibody-drug conjugate in which a drug linker represented by the above and an antibody are bonded to each other through a thioether bond, which is used for a disease ameliorated by an effect of activating antitumor immunity.
- the antibody-drug conjugate is (1) the action of promoting the increase of intratumoral CD8 positive T cells, and (2) an effect of activating intratumoral CD8 positive T cells,
- the treatment method according to [72] which has at least one action selected from the group consisting of: [74]
- the antibody-drug conjugate is (1) an action that promotes an increase in the number of dendritic cells in the tumor; (2) the action of activating dendritic cells, and (3) an action that promotes an increase in the expression level of MHC class I on cancer cells;
- the treatment method according to any one of [72] to [76] which has at least one action selected from the group consisting of: [78] The therapeutic method according to any one of [72] to [77], wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, or an anti-B7-H3 antibody.
- the therapeutic method according to [78] wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.
- the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence described in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence described in amino acid numbers 1 to 214 in SEQ ID NO: 2.
- [85] Disease is lung cancer, urothelial cancer, colon cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, gastroesophageal junction adenocarcinoma, gastrointestinal stromal tumor, cervical cancer, esophageal cancer, squamous cell carcinoma , Peritoneal cancer, liver cancer, hepatocellular carcinoma, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulva cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, neuroepithelial tissue At least one selected from the group consisting of sexual tumors, nerve sheath tumors, head and neck cancer, skin cancer, pharyngeal cancer, gallbladder cancer, bile duct cancer, mesothelioma, Paget's disease, and sarcoma [72] To the treatment method of any one of [84]. [86] The method according to [85
- a therapeutic method comprising using the compound represented by the above for a disease that is improved by an action of activating anti-tumor immunity, which is released within a tumor.
- Compound is (1) the action of promoting the increase of intratumoral CD8 positive T cells, and (2) an effect of activating intratumoral CD8 positive T cells,
- the treatment method according to [88] which has at least one action selected from the group consisting of: [90]
- the treatment method according to [88] or [89] wherein the compound has an effect of promoting formation of immune memory against a tumor.
- Compound is (1) an action that promotes an increase in the number of dendritic cells in the tumor; (2) the action of activating dendritic cells, and (3) an action that promotes an increase in the expression level of MHC class I on cancer cells;
- A indicates the binding position with the antibody
- the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence described in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence described in amino acid numbers 1 to 214 in SEQ ID NO: 2. [94] or the antibody-drug conjugate according to [95]. [97] The antibody according to [94] or [95], wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2. Drug conjugate. [98] 96.
- Cancer is lung cancer, urothelial cancer, colon cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, gastroesophageal junction adenocarcinoma, gastrointestinal stromal tumor, cervical cancer, esophageal cancer, squamous epithelium Cancer, peritoneal cancer, liver cancer, hepatocellular carcinoma, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulva cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, neuroepithelium [107] at least one selected from the group consisting of tissue tumor, nerve sheath tumor, head and neck cancer, skin cancer, pharyngeal cancer, gallbladder cancer, bile duct cancer, mesothelioma, Paget's disease, and sarcoma.
- the antibody-drug conjugate according to claim 1 [109] The antibody-drug conjugate according to [108], wherein the cancer is colorectal cancer. [110] The antibody-drug conjugate according to [108], wherein the cancer is breast cancer. [111] The antibody-drug conjugate according to any one of [93] to [110], which has an effect of activating antitumor immunity.
- [112] (1) the action of promoting the increase of intratumoral CD8 positive T cells, and (2) an effect of activating intratumoral CD8 positive T cells,
- the antibody-drug conjugate according to [113] wherein the tumor expresses an antigen against the antibody in the antibody-drug conjugate.
- the antibody-drug conjugate according to [113] wherein a part of the tumor does not express an antigen against the antibody in the antibody-drug conjugate.
- [116] (1) an action that promotes an increase in the number of dendritic cells in the tumor; (2) the action of activating dendritic cells, and (3) an action that promotes an increase in the expression level of MHC class I on cancer cells;
- the antibody-drug conjugate exhibits a stronger antitumor effect when the immune checkpoint inhibitor releases the immunosuppressive signal generated by promoting the increase in PD-L1 expression on cancer cells.
- A indicates the binding position with the antibody
- [119] (1) the action of promoting the increase of intratumoral CD8 positive T cells, and (2) an effect of activating intratumoral CD8 positive T cells,
- the antibody-drug conjugate according to [118] which has at least one action selected from the group consisting of: [120] The antibody-drug conjugate according to [118] or [119], which has an effect of promoting immune memory formation against a tumor.
- the antibody-drug conjugate of claim [120] wherein the tumor expresses an antigen against the antibody in the antibody-drug conjugate.
- the antibody-drug conjugate according to any one of [118] to [122], for use in the treatment of a disease ameliorated by at least one action selected from the group consisting of: [124] The antibody-drug conjugate according to any one of [118] to [123], wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, or an anti-B7-H3 antibody.
- the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence described in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence described in amino acid numbers 1 to 214 in SEQ ID NO: 2. [124] or the antibody-drug conjugate according to [125].
- the antibody according to [124] or [125] wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.
- Drug conjugate [128] The antibody-drug conjugate according to any one of [118] to [127], wherein the average number of drug linkers per antibody in the antibody-drug conjugate ranges from 2 to 8. [129] The antibody-drug conjugate according to any one of [118] to [127], wherein the average number of drug linkers per antibody in the antibody-drug conjugate ranges from 7 to 8. [130] The antibody-drug conjugate according to any one of [118] to [127], wherein the average number of drug linkers per antibody in the antibody-drug conjugate is in the range of 7.5 to 8.
- [131] Disease is lung cancer, urothelial cancer, colon cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, gastroesophageal junction adenocarcinoma, gastrointestinal stromal tumor, cervical cancer, esophageal cancer, squamous cell carcinoma , Peritoneal cancer, liver cancer, hepatocellular carcinoma, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulva cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, neuroepithelial tissue At least one selected from the group consisting of sex tumors, nerve sheath tumors, head and neck cancer, skin cancer, pharyngeal cancer, gallbladder cancer, bile duct cancer, mesothelioma, Paget's disease, and sarcoma [118] The antibody-drug conjugate according to any one of [130] to [130
- a compound represented by [135] (1) the action of promoting the increase of intratumoral CD8 positive T cells, and (2) an effect of activating intratumoral CD8 positive T cells, [134]
- the compound according to [134] which has at least one action selected from the group consisting of: [136]
- the compound according to [134] or [135] which has an action of promoting formation of immune memory against a tumor.
- [137] (1) an action that promotes an increase in the number of dendritic cells in the tumor; (2) the action of activating dendritic cells, and (3) an action that promotes an increase in the expression level of MHC class I on cancer cells; [134]
- A indicates the binding position with the antibody
- an antibody-drug conjugate in which a drug linker represented by the above is bound to an antibody by a thioether bond.
- the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, or an anti-B7-H3 antibody.
- the antibody in the antibody-drug conjugate is an anti-HER2 antibody.
- the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence described in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence described in amino acid numbers 1 to 214 in SEQ ID NO: 2.
- [144] 144 Use according to any one of [139] to [143], wherein the average number of drug linkers per antibody in the antibody-drug conjugate ranges from 2 to 8.
- Cancer is lung cancer, urothelial cancer, colon cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, gastroesophageal junction adenocarcinoma, gastrointestinal stromal tumor, cervical cancer, esophageal cancer, squamous epithelium Cancer, peritoneal cancer, liver cancer, hepatocellular carcinoma, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulva cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, neuroepithelium [153] At least one selected from the group consisting of tissue tumor, nerve sheath tumor, head and neck cancer, skin cancer, pharyngeal cancer, gallbladder cancer, bile duct cancer, mesothelioma, Paget's disease, and sarcoma.
- the antibody-drug conjugate is (1) the action of promoting the increase of intratumoral CD8 positive T cells, and (2) an effect of activating intratumoral CD8 positive T cells,
- the use according to [159], wherein the tumor expresses an antigen against the antibody in the antibody-drug conjugate.
- [161] The use according to [159], wherein a part of the tumor does not express an antigen against the antibody in the antibody-drug conjugate.
- the antibody-drug conjugate is (1) an action that promotes an increase in the number of dendritic cells in the tumor; (2) the action of activating dendritic cells, and (3) an action that promotes an increase in the expression level of MHC class I on cancer cells;
- the antibody-drug conjugate releases the immunosuppressive signal generated by promoting the increase in the expression level of PD-L1 on the cancer cell by the immune checkpoint inhibitor.
- the use according to any one of [139] to [162] which exhibits a stronger antitumor effect.
- Formula for the manufacture of a medicament characterized in that it is used for the treatment of diseases ameliorated by the action of activating anti-tumor immunity
- A indicates the binding position with the antibody
- the antibody-drug conjugate is (1) the action of promoting the increase of intratumoral CD8 positive T cells, and (2) an effect of activating intratumoral CD8 positive T cells,
- the use according to [164] having at least one action selected from the group consisting of: [166] The use according to [164] or [165], wherein the antibody-drug conjugate has an effect of promoting formation of immune memory against a tumor.
- [170] The use according to any one of [164] to [169], wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, anti-HER3 antibody, anti-TROP2 antibody, or anti-B7-H3 antibody.
- the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence described in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence described in amino acid numbers 1 to 214 in SEQ ID NO: 2. Use according to [170] or [171].
- [173] The use according to [170] or [171], wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.
- [174] The use according to any one of [164] to [173], wherein the average number of drug linkers per antibody in the antibody-drug conjugate ranges from 2 to 8.
- [175] The use according to any one of [164] to [173], wherein the average number of drug linkers per antibody in the antibody-drug conjugate ranges from 7 to 8.
- [176] The use according to any one of [164] to [173], wherein the average number of drug linkers per antibody in the antibody-drug conjugate is in the range of 7.5 to 8.
- Disease is lung cancer, urothelial cancer, colon cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, gastroesophageal junction adenocarcinoma, gastrointestinal stromal tumor, cervical cancer, esophageal cancer, squamous cell carcinoma , Peritoneal cancer, liver cancer, hepatocellular carcinoma, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulva cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, neuroepithelial tissue 164, at least one selected from the group consisting of sex tumors, nerve sheath tumors, head and neck cancer, skin cancer, pharyngeal cancer, gallbladder cancer,
- Compound is (1) the action of promoting the increase of intratumoral CD8 positive T cells, and (2) an effect of activating intratumoral CD8 positive T cells, The use according to [180], having at least one action selected from the group consisting of: [182] The use according to [180] or [181], wherein the compound has an action of promoting immune memory formation against a tumor.
- Compound is (1) an action that promotes an increase in the number of dendritic cells in the tumor; (2) the action of activating dendritic cells, and (3) an action that promotes an increase in the expression level of MHC class I on cancer cells;
- the present invention by administering a specific antibody-drug conjugate and an immune checkpoint inhibitor in combination, it is possible to provide a pharmaceutical composition and a treatment method that are excellent in antitumor effect and safety.
- the present invention provides a pharmaceutical composition and a treatment method for treating a disease which is improved by the action of promoting the formation of immune memory against a tumor, which comprises a specific antibody-drug conjugate. Can do.
- 1 shows the amino acid sequence of the humanized anti-HER2 antibody heavy chain (SEQ ID NO: 1).
- 2 shows the amino acid sequence of the humanized anti-HER2 antibody light chain (SEQ ID NO: 2). It is the figure which showed the life prolonging effect of each chemical
- the life-prolonging effect is compared between the single agent group and the combination group of the antibody-drug conjugate (1) and anti-PD-1 antibody (clone RMP1-14). It is the figure which showed the life prolonging effect of each chemical
- Figure 1 shows changes in tumor volume when CT26.WT-hHER2 cells or CT26.WT-mock cells were subcutaneously transplanted (re-implanted) to antibody-drug conjugate (1) treated cured mice and control mice, respectively. It is.
- Antibody-drug conjugate (1) Immune response to antigen derived from CT26.WT-hHER2 cells (IFN ⁇ -producing spleen) when CT26.WT-hHER2 cells are subcutaneously transplanted (re-implanted) to treated mice and control mice, respectively It is the figure which showed cell number.
- Antibody-drug conjugate (1) Immune response (IFN ⁇ producing spleen) to antigen derived from CT26.WT-mock cells when CT26.WT-hHER2 cells are subcutaneously transplanted (re-implanted) to treated mice and control mice, respectively It is the figure which showed cell number.
- Antibody-drug conjugate (1) Immune response to antigen derived from CT26.WT-hHER2 cells (IFN ⁇ -producing spleen) when CT26.WT-mock cells are subcutaneously transplanted (re-implanted) to treated mice and control mice, respectively It is the figure which showed cell number.
- Immune response IFN ⁇ -producing spleen
- CT26.WT-mock cell-derived antigen when CT26.WT-mock cells are subcutaneously transplanted (re-implanted) to treated mice and control mice, respectively
- IFN ⁇ -producing spleen Immune response to CT26.WT-mock cell-derived antigen when CT26.WT-mock cells are subcutaneously transplanted (re-implanted) to treated mice and control mice, respectively
- CD86 in the case of treating a bone marrow-derived dendritic cell with a compound (A) and DMSO by flow cytometry.
- MHC class II when the bone marrow-derived dendritic cells were treated with the compound (A) and DMSO by flow cytometry.
- the figure shows the number of dendritic cells in tumor lymphocytes measured by flow cytometry in the antibody-drug conjugate (1) administration group and control group in mice transplanted subcutaneously with CT26.WT-hHER2 cells. is there.
- the figure which measured the number of CD86 positive cells which occupy the dendritic cell in a tumor about the antibody-drug conjugate (1) administration group and the control group in the mouse
- the expression level of CD86 on dendritic cells in the tumor was measured by flow cytometry in the antibody-drug conjugate (1) administration group and the control group. It is the figure shown by.
- CT26.WT-hHER2 cells were subcutaneously transplanted in mice with antibody-drug conjugate (1) and control groups, and the expression level of MHC class I on cancer cells (human HER2-positive cells) was measured by flow cytometry. It is the figure which measured by and was shown by MFI.
- Flow cytometry of PD-L1 expression level on cancer cells (human HER2-positive cells) in mice administered with CT26.WT-hHER2 cells subcutaneously in the antibody-drug conjugate (1) administration group and control group It is the figure which measured by and was shown by MFI. It is the figure which measured the amount of expression of MHC class I when cancer cells were treated with compound (A) and DMSO by flow cytometry.
- FIG. 3 is a graph showing changes in tumor volume in an antibody-drug conjugate (1) administration group and a control group in a mouse model in which CT26.WT-hHER2 cells are subcutaneously transplanted into nude mice.
- FIG. 3 is a graph showing changes in tumor volume for an antibody-drug conjugate (1) administration group, a control antibody-drug conjugate administration group, and a control group in mice transplanted subcutaneously with CT26.WT-hHER2 cells. Changes in tumor volume were observed in the single-agent and combination groups of antibody-drug conjugate (1) and anti-PD-1 antibody (clone RMP1-14) in mice transplanted subcutaneously with EMT6-hHER2 cells.
- FIG. 3 is a graph showing changes in tumor volume in a single agent administration group and a combination group of an antibody-drug conjugate (1) and an anti-CD4 antibody in mice transplanted subcutaneously with CT26.WT-hHER2 cells.
- FIG. 3 is a graph showing changes in tumor volume in a single agent administration group and a combination group of an antibody-drug conjugate (1) and an anti-CD8 antibody in mice transplanted subcutaneously with CT26.WT-hHER2 cells.
- CT26.WT-hHER2 cells were subcutaneously transplanted with the antibody-drug conjugate (1) administration group and the control group, and the proportion of Granzyme B-positive cells in the tumor CD8-positive T cells was measured by flow cytometry.
- FIG. 6 is a view showing an image obtained by staining an excised tumor with an anti-CD8 antibody in an antibody-drug conjugate (1) administration group and a control group in mice transplanted subcutaneously with CT26.WT-hHER2 cells.
- CT26.WT-hHER2 cells were subcutaneously transplanted in the antibody-drug conjugate (1) administration group and the control group by analyzing the images of the excised tumor stained with anti-CD8 antibody. It is the figure which measured the number of CD8 positive cells per area. It is the figure which measured the amount of expression of MHC class I by flow cytometry when cancer cells were treated with compound (A), DM1-SMe, DM4-SMe, MMAE and DMSO.
- This figure shows the change in tumor volume for the single-agent group and combination group of antibody-drug conjugate (1) and anti-CTLA-4 antibody (clone 9H10) in mice transplanted subcutaneously with EMT6-hHER2 cells. is there.
- the antibody-drug conjugate used in the present invention has the formula
- A indicates the binding position with the antibody
- drug linker a partial structure consisting of a linker and a drug in the antibody-drug conjugate.
- This drug linker is a thiol group (in other words, a sulfur atom of a cysteine residue) formed at a disulfide bond site between antibody chains (between two heavy chains and heavy chains and between two heavy chains and light chains). Is bound to.
- the drug linker of the present invention is exatecan (IUPAC name: (1S, 9S) -1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-) which is a topoisomerase I inhibitor.
- camptothecin derivative having an antitumor effect.
- the antibody-drug conjugate used in the present invention can also be represented by the following formula.
- N is synonymous with the so-called average drug binding number (DAR; Drug-to-Antibody Ratio), and indicates the average number of drug linkers bound per antibody.
- DAR Drug-to-Antibody Ratio
- the antibody-drug conjugate used in the present invention has an effect of activating anti-tumor immunity.
- activate anti-tumor immunity refers to promoting the exertion of an anti-tumor effect by activating at least one selected from the group consisting of T cells and B cells (Bracci L . Et al., Cell Death Differ. (2014) 21, 15-25, Chen DS. Et al., Immunity (2013) 39, 1-10, Andersen MH. Et al., Journal of Investigative Dermatology (2006) 126 , 32-41).
- the antibody-drug conjugate used in the present invention promotes the exertion of the antitumor effect by activating at least one selected from the group consisting of T cells and B cells. Confirmed by comparing the anti-tumor effect in mice with normal immune function and the anti-tumor effect in mice (nude mice) with impaired T cell and B cell immune functions can do.
- the antibody-drug conjugate used in the present invention is: (1) the action of promoting the increase of intratumoral CD8 positive T cells, and (2) an effect of activating intratumoral CD8 positive T cells, Having at least one action selected from the group consisting of
- the “effect of promoting the increase of intratumoral CD8-positive T cells” possessed by the antibody-drug conjugate used in the present invention is, for example, a living cell in an antibody-drug conjugate administration group and a control group in a tumor-bearing mouse. It can be confirmed by measuring the proportion of CD45, CD3, and CD8 positive cells (CD8 positive T cells) in the cells using flow cytometry and examining the increase rate. In addition, in the tumor-bearing mice, for the antibody-drug conjugate administration group and the control group, an image of the excised tumor stained with anti-CD8 antibody was analyzed, and the number of CD8 positive cells per unit area in the tumor was measured and increased. It can also be confirmed by examining the rate.
- the “effect of activating intratumoral CD8-positive T cells” possessed by the antibody-drug conjugate used in the present invention is, for example, the CD8-positive T for the antibody-drug conjugate administration group and the control group in cancer-bearing mice. It can be confirmed by measuring the proportion of Granzyme B positive cells in the cells using flow cytometry and examining the rate of increase. Moreover, it can also confirm by measuring the ratio of GranzymeB positive cell to a living cell using flow cytometry, and investigating the increase rate.
- the antibody-drug conjugate used in the present invention has an action of promoting the formation of immune memory against tumors. This action contributes to the above-mentioned “action of activating anti-tumor immunity”.
- T cells receive tumor-derived antigens from dendritic cells and cancer cells and are activated to exert an immune response and exert an antitumor effect.
- immune memory formation against tumor means that memory T cells are generated from T cells upon presentation of tumor-derived antigens, thereby forming a memory of immune responses to the antigens.
- a continuous antitumor effect can be exerted on a tumor having the same antigen, and an antitumor effect can be exerted again when a tumor having the antigen recurs.
- the antibody-drug conjugate used in the present invention has an “effect of promoting the formation of an immune memory against a tumor” by, for example, administering an antibody-drug conjugate to a tumor-bearing mouse, and then returning it to a mouse whose tumor has completely regressed. This can be confirmed by transplanting a tumor and measuring the degree of inhibition of tumor growth (recurrence). It can also be confirmed by removing the spleen from the mouse, adding an antigen derived from a tumor, and measuring the rate of increase in immune response (for example, the number of spleen cells producing IFN ⁇ ).
- the antibody-drug conjugate used in the present invention includes not only a tumor expressing an antigen against the antibody in the antibody-drug conjugate but also an antigen against the antibody in the antibody-drug conjugate in the same individual. It has the effect of promoting immune memory formation even for tumors that are not expressed.
- the antibody in the antibody-drug conjugate is an anti-HER2 antibody
- the antibody in the antibody-drug conjugate is an anti-HER2 antibody
- the antibody-drug conjugate used in the present invention is (1) an action that promotes an increase in the number of dendritic cells in the tumor; (2) the action of activating dendritic cells, and (3) an action that promotes an increase in the expression level of MHC class I on cancer cells; Having at least one action selected from the group consisting of These actions contribute to the above-mentioned “action for promoting the formation of immune memory against tumors”, and thus contribute to the above-mentioned “action for activating anti-tumor immunity”.
- the “effect of promoting the increase in the number of dendritic cells in the tumor” possessed by the antibody-drug conjugate used in the present invention is, for example, CD45 for the antibody-drug conjugate administration group and the control group in tumor-bearing mice. It can be confirmed by measuring the proportion of CD11c, MHC class II, and CD45-positive cells (dendritic cells, DC) in the positive cells (lymphocyte cells) using flow cytometry and examining the increase rate.
- CD45 for the antibody-drug conjugate administration group and the control group in tumor-bearing mice. It can be confirmed by measuring the proportion of CD11c, MHC class II, and CD45-positive cells (dendritic cells, DC) in the positive cells (lymphocyte cells) using flow cytometry and examining the increase rate.
- the “effect of activating dendritic cells” possessed by the antibody-drug conjugate used in the present invention is, for example, CD86 (activation marker) for the antibody-drug conjugate administration group and the control group in cancer-bearing mice. It can be confirmed by measuring the rate of dendritic cells expressing the amount using flow cytometry and examining the rate of increase. In addition, in an antibody-drug conjugate administration group and a control group in a tumor-bearing mouse, measure the expression rate (MFI (mean fluorescence intensity)) on dendritic cells by flow cytometry and examine the rate of increase. Can also be confirmed.
- MFI mean fluorescence intensity
- the “effect of promoting the increase in the expression level of MHC class I on cancer cells” possessed by the antibody-drug conjugate used in the present invention is, for example, an antibody-drug conjugate administration group and a control group in cancer-bearing mice. Can be confirmed by measuring the expression rate (MFI) of MHC class I on cancer cells by flow cytometry and examining the rate of increase.
- MFI expression rate
- the antibody-drug conjugate used in the present invention may have an action of promoting an increase in PD-L1 expression level on cancer cells.
- the antibody-drug conjugate can exhibit a stronger antitumor effect by releasing the immunosuppressive signal generated by the immune checkpoint inhibitor. Therefore, the antibody-drug conjugate used in the present invention can be expected to have a stronger antitumor effect when used in combination with an immune checkpoint inhibitor.
- the “effect of promoting the increase in the PD-L1 expression level on cancer cells” possessed by the antibody-drug conjugate used in the present invention is, for example, an antibody-drug conjugate administration group in a cancer-bearing mouse and The control group can be confirmed by measuring the expression rate (MFI) of PD-L1 on cancer cells by flow cytometry and examining the increase rate.
- MFI expression rate
- the linker moiety is cleaved after moving into the cancer cell
- compound (A) Is released (hereinafter referred to as “compound (A)”).
- Compound (A) is considered to be the main body of the antitumor activity of the antibody-drug conjugate used in the present invention, and has been confirmed to have topoisomerase I inhibitory activity (Ogitani Y. et al., Clinical Cancer Research, 2016, Oct 15; 22 (20): 5097-5108,108Epub 2016 Mar 29).
- Compound (A) has an action of activating dendritic cells and an action of promoting an increase in the expression level of MHC class I on cancer cells.
- Compound (A) has an "activate effect on dendritic cells". For example, CD86 expression when bone marrow-derived dendritic cells are treated with compound (A) and DMSO is measured by flow cytometry. This can be confirmed by examining the rate.
- Compound (A) has an “activating increase in the expression level of MHC ⁇ ⁇ class I on cancer cells”, for example, the expression level of MHC class I when cancer cells are treated with compound (A) and DMSO. It can be confirmed by measuring with cytometry and examining the rate of increase.
- the antibody-drug conjugate used in the present invention has the “action of activating dendritic cells” and the “action of promoting the increase in the expression level of MHC class I on cancer cells” possessed by the compound (A). This is the same action as “the action of activating dendritic cells” and “the action of promoting the increase in the expression level of MHC class I on cancer cells”.
- the compound (A) is a compound released from the antibody-drug conjugate used in the present invention after the antibody-drug conjugate used in the present invention has migrated to cancer cells. .
- a pharmaceutical composition that releases compound (A) in a tumor is similar to the antibody-drug conjugate used in the present invention.
- the pharmaceutical composition that releases the compound (A) in the tumor is expected to have the effect of promoting the formation of immune memory against the tumor, like the antibody-drug conjugate used in the present invention.
- the compound (A) is a compound produced from the antibody-drug conjugate used in the present invention after the antibody-drug conjugate used in the present invention has migrated to cancer cells.
- a pharmaceutical composition that releases compound (A) in a tumor is similar to the antibody-drug conjugate used in the present invention.
- the antibody-drug conjugate used in the present invention is also known to have a bystander effect (Ogitani Y. et al., Cancer Science (2016) 107, 1039-1046). This bystander effect is due to the fact that the compound (A) released after the antibody-drug conjugate used in the present invention is internalized in the target-expressing cancer cell, the nearby cancer cell not expressing the target Is exerted by exerting an anti-tumor effect.
- the bystander effect of the antibody-drug conjugate used in the present invention is exhibited as an excellent antitumor effect even when used in combination with an immune checkpoint inhibitor.
- the antibody used for the production of the antibody-drug conjugate according to the present invention may be derived from any species, but is preferably an antibody derived from human, rat, mouse and rabbit. If the antibody is derived from a species other than human, it is preferably chimerized or humanized using well-known techniques.
- the antibody of the present invention may be a polyclonal antibody or a monoclonal antibody, but a monoclonal antibody is preferred.
- the antibody used for the production of the antibody-drug conjugate according to the present invention preferably has a property capable of targeting cancer cells, and can recognize cancer cells and can bind to cancer cells. Those having the characteristics of being taken up and internalized in cancer cells and / or the cell-killing activity against cancer cells are preferred.
- the binding of the antibody to cancer cells can be confirmed using flow cytometry.
- Incorporation of antibodies into cancer cells is as follows: (1) An assay that uses a secondary antibody that binds to a therapeutic antibody (fluorescent label) to visualize the antibodies taken into the cells with a fluorescence microscope (Cell Death and Differentiation (2008 ) 15, 751-761), (2) Assays that measure the amount of fluorescence incorporated into cells using a secondary antibody (fluorescent label) that binds to the therapeutic antibody (Molecular Biology of the Cell Vol.
- the antitumor activity of the antibody can be confirmed in vitro by measuring the activity of inhibiting cell proliferation.
- cancer cell lines overexpressing the target protein of the antibody can be cultured, and antibodies can be added to the culture system at various concentrations, and the inhibitory activity against focus formation, colony formation, and spheroid growth can be measured.
- antitumor activity can be confirmed by administering an antibody to a nude mouse transplanted with a cancer cell line highly expressing the target protein and measuring the change in the cancer cell.
- the antibody itself has an antitumor effect
- the antibody-drug conjugate is bound with a compound that exhibits an antitumor effect
- the antitumor effect of the antibody itself is not essential.
- the antibody has a property of internalizing and transferring into the cancer cells.
- the antibody used for the production of the antibody-drug conjugate according to the present invention can be obtained by known means. For example, it can be obtained by immunizing an animal with a polypeptide serving as an antigen, and collecting and purifying an antibody produced in the living body, using a method commonly practiced in this field.
- the origin of the antigen is not limited to humans, and animals can be immunized with antigens derived from animals other than humans such as mice and rats.
- an antibody applicable to a human disease can be selected by examining the cross-reactivity between an antibody that binds to the obtained heterologous antigen and a human antigen.
- a hybridoma can be established by fusing an antibody-producing cell that produces an antibody against an antigen and a myeloma cell to obtain a monoclonal antibody.
- the antigen can be obtained by causing a host cell to produce a gene encoding an antigen protein by genetic manipulation.
- a vector capable of expressing an antigen gene may be prepared, introduced into a host cell to express the gene, and the expressed antigen may be purified.
- An antibody can also be obtained by using a method for immunizing an animal with an antigen-expressing cell or a cell line expressing the antigen by genetic manipulation as described above.
- the antibody used for the production of the antibody-drug conjugate according to the present invention is a genetically engineered antibody that has been artificially modified for the purpose of reducing the heteroantigenicity to humans, such as a chimeric antibody, A humanized antibody is preferable, or an antibody having only the gene sequence of a human-derived antibody, that is, a human antibody is preferable. These antibodies can be produced using known methods.
- chimeric antibody examples include antibodies in which the variable region and the constant region of the antibody are different from each other, for example, a chimeric antibody in which the variable region of a mouse or rat-derived antibody is joined to a human-derived constant region (Proc.cNatl. Acad). .Sci. USA, 81, 6851-6855, (1984)).
- antibodies As humanized antibodies, antibodies (Nature (1986) 321, p.522-525) in which only the complementarity determining region (CDR) of a heterologous antibody is incorporated into a human-derived antibody, In addition to antibody CDR sequences, amino acid residues of some frameworks of heterologous antibodies are also transplanted into human antibodies (WO 90/07861), gene conversion mutagenesis strategy An antibody (U.S. Pat. No. 5,721,337) that has been humanized by use can be mentioned.
- CDR complementarity determining region
- human antibody an antibody prepared using a human antibody-producing mouse having a human chromosome fragment containing heavy and light chain genes of a human antibody (Tomizuka, K. et al., Nature Genetics (1997) 16, p. 133-143; Kuroiwa, Y. et. Al., Nucl. Acids Res. (1998) 26, p.3447-3448; Yoshida,; H. Et. Al., Animal Cell Technology: Basic and Applied Aspects vol.10, p. 69-73 (Kitagawa, Y., Matsuda, T. and Iijima, S. eds.), Kluwer Academic Publishers, 1999; Tomizuka, K. et.
- antibodies obtained by phage display selected from a human antibody library (Wormstone, I. M. et. Al, Investigative Ophthalmology & Visual Science. (2002) 43 (7), p.2301-2308; Mé, S. et. al., Briefings in Functional Genomics and Proteomics (2002), 1 (2), p.189-203; Siriwardena, D. et. al., Ophthalmology (2002) 109 (3), p.427-431 etc. See also).
- the antibody used for the production of the antibody-drug conjugate according to the present invention includes a modified antibody.
- the modified product means a product obtained by chemically or biologically modifying the antibody according to the present invention.
- Chemical modifications include chemical modifications having a chemical moiety attached to the amino acid backbone, a chemical moiety attached to an N-linked or O-linked carbohydrate chain, and the like.
- Biological modifications include post-translational modifications (eg, addition of N- or O-linked sugar chains, N- or C-terminal processing, deamidation, aspartic acid isomerization, methionine oxidation, etc. ), And those in which a methionine residue is added to the N-terminus by expression using a prokaryotic host cell.
- those labeled to enable detection or isolation of the antibody or antigen according to the present invention for example, an enzyme label, a fluorescent label, and an affinity label are also included in the meaning of such a modified form.
- a modified antibody according to the present invention is useful for improving antibody stability and blood retention, reducing antigenicity, and detecting or isolating antibodies or antigens.
- the antibody according to the present invention includes an antibody in which the sugar chain modification is regulated.
- the antibody according to the present invention also includes the modified antibody and a functional fragment of the antibody, a deletion in which 1 or 2 amino acids are deleted from the heavy chain carboxyl terminus, and amidated Such deletion forms (for example, heavy chain in which the proline residue at the carboxyl terminal site is amidated) and the like are also included.
- the carboxyl-terminal deletion of the heavy chain of the antibody according to the present invention is not limited to the above type.
- the two heavy chains constituting the antibody according to the present invention may be any one of the full length and the heavy chain selected from the group consisting of the above-mentioned deletion forms, or a combination of any two of them It may be a thing.
- the amount ratio of each deletion can be affected by the type and culture conditions of the cultured mammalian cells that produce the antibody according to the present invention, but the antibody according to the present invention preferably has a carboxyl terminus at both of the two heavy chains. In which one amino acid residue is deleted.
- Examples of the isotype of the antibody according to the present invention include IgG (IgG1, IgG2, IgG3, IgG4), and preferably IgG1 or IgG2.
- the antibody that can be used for the production of the antibody-drug conjugate according to the present invention is not particularly limited.
- anti Examples include CD22 antibody, anti-CD70 antibody, anti-PSMA antibody, anti-CEA antibody, and anti-Mesothelin antibody, preferably, anti-HER2 antibody, anti-HER3 antibody, anti-TROP2 antibody, and anti-B7-H3 antibody. More preferred examples include anti-HER2 antibodies.
- anti-HER2 antibody specifically binds to HER2 (Human Epidermal Growth FactorReceptor Type 2; ErbB-2), and preferably has an activity to internalize in HER2-expressing cells by binding to HER2.
- HER2 Human Epidermal Growth FactorReceptor Type 2
- ErbB-2 Human Epidermal Growth FactorReceptor Type 2
- anti-HER2 antibody examples include Trastuzumab (US Patent No. 5821337) and Pertuzumab (International Publication No. 01/00245), and preferably include trastuzumab. .
- “trastuzumab” is sometimes called HERCEPTIN (registered trademark), huMAb4D5-8, rhuMAb4D5-8, and is a heavy chain consisting of the amino acid sequences described in amino acid numbers 1 to 449 in SEQ ID NO: 1 (FIG. 1). And a humanized anti-HER2 antibody comprising a light chain comprising the amino acid sequence of amino acid numbers 1 to 214 in SEQ ID NO: 2 (FIG. 2).
- Suitable anti-HER2 antibodies used for the production of antibody-drug conjugates according to the present invention are: (1) an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO: 2, or (2) An antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.
- anti-HER3 antibody specifically binds to HER3 (HumanuEpidermal Growth FactorReceptor Type 3; ErbB-3), and preferably has an activity of internalizing in HER3-expressing cells by binding to HER3.
- HER3 HumanuEpidermal Growth FactorReceptor Type 3; ErbB-3
- the antibody which has is shown.
- anti-HER3 antibody examples include patritumab (Patritumab; U3-1287), U1-59 (International Publication No. 2007/077028), MM-121 (Seribantumab), the anti-ERBB3 antibody described in International Publication No. 2008/100624, RG -7116 (Lumretuzumab) and LJM-716 (Elgemtumab) can be mentioned, and patritumab and U1-59 are preferable.
- patritumab and U1-59 are preferable.
- anti-TROP2 antibody specifically binds to TROP2 (TACSTD2: Tumor-associated calcium signal transducer 2; EGP-1), and preferably internalizes in TROP2-expressing cells by binding to TROP2.
- TROP2 Tumor-associated calcium signal transducer 2; EGP-1
- anti-TROP2 antibody examples include hTINA1-H1L1 (International Publication No. 2015/098099).
- anti-B7-H3 antibody refers to an antibody that specifically binds to B7-H3, and preferably has an activity of internalizing in B7-H3 expressing cells by binding to B7-H3. .
- Examples of the anti-B7-H3 antibody include M30-H1-L4 (International Publication No. 2014/057687).
- Drug linker intermediates used in the production of antibody-drug conjugates The drug linker intermediate used in the production of the antibody-drug conjugate according to the present invention is represented by the following formula.
- the above drug linker intermediate is N- [6- (2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl) hexanoyl] glycylglycyl-L-phenylalanyl-N-[(2- ⁇ [(1S, 9S) -9-Ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H, 12H-benzo [ de] pyrano [3 ′, 4 ′: 6,7] indolizino [1,2-b] quinolin-1-yl] amino ⁇ -2-oxoethoxy) methyl] glycinamide, It can be produced with reference to the descriptions of International Publication No. 2014/057687, International Publication No. 2015/098099, International Publication No. 2015/115091, International Publication No. 2015/155998, and the like.
- the antibody-drug conjugate used in the present invention can be produced by reacting the aforementioned drug linker intermediate with an antibody having a thiol group (also referred to as a sulfhydryl group).
- Antibodies having a sulfhydryl group can be obtained by methods well known to those skilled in the art (Hermanson, G. T, Bioconjugate Techniques, pp.56-136, pp.456-493, Academic Press (1996)).
- a reducing agent such as tris (2-carboxyethyl) phosphine hydrochloride (TCEP) is used in an amount of 0.3 to 3 molar equivalents per interchain disulfide within the antibody, and a chelating agent such as ethylenediaminetetraacetic acid (EDTA) is used.
- TCEP tris (2-carboxyethyl) phosphine hydrochloride
- EDTA ethylenediaminetetraacetic acid
- an antibody-drug conjugate in which 2 to 8 drug equivalents are bound per antibody using 2 to 20 molar equivalents of drug linker intermediate per antibody having a sulfhydryl group. it can.
- UV method UV absorbance of the antibody-drug conjugate and its conjugation precursor at two wavelengths of 280 nm and 370 nm
- HPLC method HPLC measurement
- anti-HER2 antibody-drug conjugate refers to an antibody-drug conjugate in which the antibody in the antibody-drug conjugate is an anti-HER2 antibody.
- the average number of drug linkers per antibody of the anti-HER2 antibody-drug conjugate used in the present invention is preferably 2 to 8, more preferably 3 to 8, and even more preferably 7 to 8, even more preferably 7.5 to 8, and even more preferably about 8.
- the anti-HER2 antibody-drug conjugate used in the present invention can be produced with reference to the description in International Publication No. 2015/115091.
- anti-HER3 antibody-drug conjugate refers to an antibody-drug conjugate in which the antibody in the antibody-drug conjugate is an anti-HER3 antibody.
- the average number of drug linkers per antibody of the anti-HER3 antibody-drug conjugate used in the present invention is preferably 2 to 8, more preferably 3 to 8, and even more preferably 7 to 8, even more preferably 7.5 to 8, and even more preferably about 8.
- the anti-HER3 antibody-drug conjugate used in the present invention can be produced with reference to the description in International Publication No. 2015/155998.
- anti-TROP2 antibody-drug conjugate refers to an antibody-drug conjugate in which the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.
- the average number of drug linkers per antibody of the anti-TROP2 antibody-drug conjugate used in the present invention is preferably 2 to 8, more preferably 3 to 5, even more preferably 3.5 to 4.5, even more preferably about 4.
- the anti-TROP2 antibody-drug conjugate used in the present invention can be produced with reference to the description in International Publication No. 2015/098099.
- anti-B7-H3 antibody-drug conjugate refers to an antibody-drug conjugate in which the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.
- the average number of drug linkers per antibody of the anti-B7-H3 antibody-drug conjugate used in the present invention is preferably 2 to 8, more preferably 3 to 5, and even more preferably Is from 3.5 to 4.5, and even more preferably about 4.
- the anti-B7-H3 antibody-drug conjugate used in the present invention can be produced with reference to the description in International Publication No. 2014/057687.
- immune checkpoint inhibitor refers to a drug that inhibits the immunosuppressive system and activates tumor immunity.
- the immune checkpoint inhibitor used in the present invention is not particularly limited, and preferably includes anti-PD-1 antibody, anti-PD-L1 antibody, and anti-CTLA-4 antibody, and more preferably Can include anti-PD-1 antibodies and anti-PD-L1 antibodies.
- anti-PD-1 antibody means PD-1 and its binding partner, PD-L1 by specifically binding to PD-1 (Programmed cell death-1; CD279; PDCD1). And an antibody having an action of reducing, inhibiting and / or interfering with signal transduction resulting from the interaction with PD-L2.
- the anti-PD-1 antibody used in the present invention is not particularly limited as long as clinical effectiveness and safety have been confirmed, but preferably, nivolumab (International Publication No. 2006/121168). Etc.), and Pembrolizumab (International Publication No. 2008/156712 etc.).
- a commercially available anti-PD-1 antibody for research eg, clone RMP1-14
- clone RMP1-14 clone RMP1-14
- anti-PD-L1 antibody refers to PD-L1 and its binding partner, PD-L1 by specifically binding to PD-L1 (ProgrammedProgramcell death ligand 1; CD274; B7-H1).
- the anti-PD-L1 antibody used in the present invention is not particularly limited as long as clinical efficacy and safety have been confirmed, but preferably, atezolizumab (International Publication No. 2010/077634) Etc.), Durvalumab (International Publication No. 2011/066389 etc.), and Avelumab (International Publication No.
- anti-CTLA-4 antibody refers to CTLA-4 (CytotoxictoT-lymphocyte-associated-protein 4; CD152) by specifically binding CTLA-4 and its binding partner, B7. 1 shows an antibody having an action of reducing, inhibiting and / or interfering with signal transduction resulting from interaction with 1 (CD80) or B7.2 (CD86).
- the anti-CTLA-4 antibody used in the present invention is not particularly limited as long as clinical efficacy and safety have been confirmed, but preferably, ipilimumab (International Publication No. 2001/014424) And Tremelimumab (International Publication No. 2000/037504 etc.).
- a commercially available anti-CTLA-4 antibody for research eg, clone 9H10 or the like can also be used for the purpose of confirming the combined effect with the antibody-drug conjugate used in the present invention in preclinical studies.
- the pharmaceutical composition and therapeutic method of the present invention are characterized in that the antibody-drug conjugate and the immune checkpoint inhibitor are contained in different preparations as active ingredients, and are administered simultaneously or at different times.
- the antibody-drug conjugate and the immune checkpoint inhibitor may be contained and administered as active ingredients in a single preparation.
- the antibody-drug conjugate according to the present invention may be contained and administered as an active ingredient in a single preparation for the treatment of diseases improved by the action of activating antitumor immunity. .
- the pharmaceutical composition and treatment method of the present invention can be used for the treatment of cancer, and preferably, lung cancer (including non-small cell lung cancer), urothelial cancer, colon cancer (colorectal cancer and (Including colon cancer and rectal cancer), prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer (sometimes called gastric adenocarcinoma), gastroesophageal junction adenocarcinoma, gastrointestinal stromal tumor, Cervical cancer, esophageal cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, Selected from the group consisting of plasmacytoma, myeloma, neuroepithelial tissue tumor, nerve sheath tumor, head and neck cancer, skin cancer, pharyngeal cancer, gallbladder cancer, bil
- the pharmaceutical composition and treatment method of the present invention can be selected and used as a drug for pharmacotherapy, which is the main treatment method for cancer.
- pharmacotherapy which is the main treatment method for cancer.
- the growth of cancer cells is delayed and proliferated. It can suppress and even destroy cancer cells.
- These effects can achieve relief from cancer symptoms and improvement of QOL in cancer patients, and achieve therapeutic effects while maintaining the lives of cancer patients. Even when cancer cells are not destroyed, long-term survival can be achieved while achieving higher QOL in cancer patients by suppressing or controlling the growth of cancer cells.
- the pharmaceutical composition and treatment method of the present invention can also be used as a drug combined with other therapies in adjuvant therapy, such as surgery, radiation therapy, hormone therapy, etc. Can be combined. Furthermore, it can also be used as a drug for pharmacotherapy in neoadjuvant therapy.
- the pharmaceutical composition and treatment method of the present invention can be expected to have a preventive effect of suppressing the proliferation of even fine metastatic cancer cells and further destroying them.
- a preventive effect of suppressing the proliferation of even fine metastatic cancer cells and further destroying them For example, an effect of suppressing and destroying cancer cells in a body fluid during a metastasis process and an effect of suppressing and destroying fine cancer cells immediately after implantation in any tissue can be expected. Therefore, suppression of cancer metastasis, especially after surgical removal of cancer, can be expected.
- the pharmaceutical composition and the treatment method of the present invention can be applied to a patient as a systemic therapy or applied locally to a cancer tissue to expect a therapeutic effect.
- the pharmaceutical composition and treatment method of the present invention can be preferably used for mammals, but more preferably can be used for humans.
- the pharmaceutical composition of the present invention can be administered as a pharmaceutical composition comprising one or more pharmaceutically compatible ingredients.
- the substance used in the pharmaceutical composition of the present invention can be applied by appropriately selecting from the dosage additives and the like commonly used in this field in the dosage and concentration.
- the pharmaceutical composition typically includes one or more pharmaceutical carriers (eg, sterile liquids).
- Liquids here include, for example, water and oils (oils of petroleum, animal, vegetable or synthetic origin).
- the oil may be, for example, peanut oil, soybean oil, mineral oil, sesame oil and the like.
- Water is a more typical carrier when the pharmaceutical composition is administered intravenously.
- Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
- Suitable pharmaceutical excipients can be appropriately selected from those known in the art.
- the composition can also include minor amounts of wetting or emulsifying agents, or pH buffering agents, if desired.
- suitable pharmaceutical carriers are described in “Remington ’s Pharmaceutical Sciences” by E. W. Martin. The formulation corresponds to the mode of administration.
- Introduction routes can include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, and subcutaneous routes.
- Administration can be, for example, by infusion or bolus injection.
- administration of the antibody-drug conjugate and immune checkpoint inhibitor used in the present invention is by infusion.
- Parenteral administration is the preferred route of administration.
- the pharmaceutical composition is formulated according to routine procedures as a pharmaceutical composition adapted for intravenous administration to humans.
- compositions for intravenous administration are solutions in sterile isotonic aqueous buffer.
- the pharmaceutical composition may also include a solubilizer and a local anesthetic (eg, lignocaine) to ease pain at the site of the injection.
- the ingredients are either separately or together in a unit dosage form, for example, as a dry lyophilized powder or anhydrous concentrate in a sealed container such as an ampoule or sachet indicating the amount of active agent. Mixed and supplied either.
- the pharmaceutical composition is in a form to be administered by infusion, it can be dispensed, for example, with an infusion bottle containing sterile pharmaceutical grade water or saline.
- an ampoule of sterile water for injection or saline can be provided, for example, so that the ingredients can be mixed prior to administration.
- the pharmaceutical composition and treatment method of the present invention may contain a cancer therapeutic agent other than the antibody-drug conjugate and immune checkpoint inhibitor according to the present invention.
- the pharmaceutical composition and treatment method of the present invention can be administered in combination with other cancer therapeutic agents, thereby enhancing the antitumor effect.
- Other cancer therapeutic agents used for such a purpose may be administered to an individual separately or sequentially at the same time as the pharmaceutical composition of the present invention, or at different administration intervals. May be.
- Such cancer therapeutic agents include 5-fluorouracil (5-FU), pertuzumab, trastuzumab, paclitaxel, carboplatin, cisplatin, gemcitabine, capecitabine (capitebine) ), Irinotecan (CPT-11), Docetaxel, Pemetrexed, Sorafenib, Vinblastin, Vinorelbine, Everolims, Nepicin, Tanepimycin (Bevacizumab), oxaliplatin (Oxaliplatin), Lapatinib (Lapatinib), trastuzumab emtansine (T-DM1) or the drug described in WO2003 / 038043, and LH-RH analog (leuprorelin ( Leuprorelin), Goseleri (Goserelin, etc.), estramustine phosphate (Estramustine ⁇ Phosphate), estrogen antagonists (Tamoxifen, raloxifene, etc.),
- Such a pharmaceutical composition can be formulated as a freeze-dried preparation or a liquid preparation as a preparation having a selected composition and the required purity.
- a pharmaceutical composition When formulated as a lyophilized formulation, it may be a formulation containing appropriate formulation additives used in this field.
- liquid preparations can be formulated as liquid preparations containing various preparation additives used in this field.
- the composition and concentration of the pharmaceutical composition vary depending on the administration method, the antibody-drug conjugate and immune checkpoint inhibitor contained in the pharmaceutical composition of the present invention have an affinity for an antigen, that is, a dissociation constant ( In terms of (Kd value), the higher the affinity (the lower the Kd value), the more effective the drug can be exerted even at a small dose. Therefore, the dosage of the antibody-drug conjugate and immune checkpoint inhibitor can be set based on the affinity situation with the antigen.
- Kd value dissociation constant
- the antibody-drug conjugate and immune checkpoint inhibitor according to the present invention are administered to humans, for example, about 0.001 to 100 mg / kg may be administered once or once every 1 to 180 days. It may be administered once.
- examples of the administration method include a method of administering 0.8 mg / kg to 8 mg / kg once every 3 weeks.
- Examples of the dosage include 0.8 mg / kg, 1.6 mg / kg, 3.2 mg / kg, 5.4 mg / kg, 6.4 mg / kg, 7.4 mg / kg, and 8 mg / kg.
- Administration may be once every three weeks (q3w), but once a week (q1w), once every two weeks (q2w), or once every four weeks (q4w) .
- antibody-drug conjugate (1) in which a drug linker represented by the above and an anti-HER2 antibody are bound by a thioether bond was produced.
- Antibody-drug conjugate (1) (Drug-to-Antibody Ratio: 7.6) was diluted with a dedicated solvent (10 mM Histidine, 10% Trehalose, 0.02% Polysorbate 20, pH 5.5).
- Anti-PD-1 antibody (clone RMP1-14) was purchased from Bio X Cell and diluted with DPBS (SIGMA-ALDRICH). At the time of administration, a dose of 10 mL / kg was administered via the tail vein.
- CT26.WT-hHER2 cells in which a human HER2 gene was introduced into a mouse colon cancer cell line CT26.WT (CRL2638) purchased from American Type Culture Collection using a retroviral vector were used. These cells express human HER2 protein on the cell membrane.
- CT26.WT-hHER2 cells were suspended in physiological saline, 5.0 ⁇ 10 6 cells were subcutaneously transplanted into the right axilla of BALB / c mice, and grouped randomly after 6 days (Day 0).
- the antibody-drug conjugate (1) was administered at a dose of 10 mg / kg twice a day on Days 0 and 7 by tail vein.
- Anti-PD-1 antibody was administered at a dose of 2.5 mg / kg on Days 0, 3, 7, 10 and 14 for a total of 5 times via the tail vein.
- a group in which the antibody-drug conjugate (1) and anti-PD-1 antibody were administered in combination and a control group were administered as a group in which the exclusive solvent for the antibody-drug conjugate (1) was administered.
- the number of mice in each group was 6, and the tumor volume was measured until Day 43.
- the results are shown in FIG.
- the Kaplan-Meier curve when the tumor volume exceeded 3000 mm 3 was used as the end point was described.
- the vertical axis represents the survival rate (%), and the horizontal axis represents the number of days from the first administration day.
- the control group decreased from Day 17 and all cases were euthanized by Day 24.
- the antibody-drug conjugate (1) group decreased from Day 28 and survived by Day 43.
- the anti-PD-1 antibody group decreased from Day 21 and 2 cases survived by Day 43. Furthermore, all of these two-drug combination groups survived until Day 43. Also, no weight loss of mice was observed in all groups in this study. Based on the above, the antitumor effect of single administration of both drugs was confirmed, and it was confirmed that the effect was dramatically enhanced by the combined use of two drugs.
- the day when the estimated tumor volume exceeded 3000 mm 3 was defined as the event occurrence day (the day of death).
- the multiplicity-adjusted P value was described with 4 digits after the decimal point, and P ⁇ 0.05 (two-sided test) was considered significant.
- the results are shown in FIG.
- the combination group showed a significantly superior antitumor effect (P ⁇ 0.0001).
- CT26.WT-hHER2 cells or CT26.WT-mock cells are subcutaneously implanted into the left axilla of each of the antibody-drug conjugate (1) -treated cured mouse and the control mouse ( Tumor volume was measured until re-implantation, Day 0), Day 17. The number of mice in each group was nine. The results are shown in FIG. The vertical axis represents the tumor volume (mm 3 ), and the horizontal axis represents the number of days after reimplantation. When CT26.WT-hHER2 cells or CT26.WT-mock cells were re-implanted into control mice, tumor growth was observed.
- the spleen cells of the antibody-drug conjugate (1) -treated cured mice were derived from CT26.WT-hHER2 cells compared to the spleen cells of the control mice.
- the antibody-drug conjugate (1) has an action of promoting the formation of immune memory against the tumor.
- the effect was observed not only on tumors expressing HER2, but also on tumors of the same origin that do not express HER2.
- the antibody-drug conjugate used in the present invention includes not only a tumor expressing an antigen against the antibody in the antibody-drug conjugate but also an antigen against the antibody in the antibody-drug conjugate within the same individual. It has been shown to have an effect of promoting immune memory formation even for tumors that are not expressed.
- Compound (A) was added to the induced dendritic cell culture at 0.0625 ⁇ M, 0.125 ⁇ M, 0.25 ⁇ M, 0.5 ⁇ M, and 1 ⁇ M.
- DMSO was added in the same amount as compound (A).
- FIG. 10 and FIG. 11 show the results of measuring the expression levels of CD86 and MHC class II by flow cytometry for CD11c positive cells. Compared with DMSO as a control, it was confirmed that the expression level of both dendritic cell maturation / activation markers CD86 and MHC-class II was increased by treatment with compound (A).
- the results of Evaluation Example 5 indicate that the compound (A) itself, which is a drug released from the antibody-drug conjugate (1), has an action of activating dendritic cells.
- the “effect of activating dendritic cells” possessed by compound (A) is the same action as the “activity of activating dendritic cells” possessed by the antibody-drug conjugate used in the present invention.
- Compound (A) is a compound produced from the antibody-drug conjugate used in the present invention after the antibody-drug conjugate used in the present invention has migrated to cancer cells. Therefore, even if the antibody portion is an antibody-drug conjugate other than the anti-HER2 antibody, it is considered that the antibody portion has the same action.
- FIGS. 15 The results are shown in FIGS. It was confirmed that the expression level of MHC class I on cancer cells (human HER2-positive cells) was significantly increased by administration of antibody-drug conjugate (1) (FIG. 15). MHC class I is a molecule necessary for T cells to recognize cancer cells. Therefore, it was suggested that the antibody-drug conjugate (1) activates anti-tumor immunity by promoting an increase in the expression level of MHC class I on cancer cells. It was also confirmed that the expression level of PD-L1 on cancer cells was significantly increased by the antibody-drug conjugate (1) (FIG. 16). PD-L1 is known to act on PD-1 on T cells and give an immunosuppressive signal.
- antibody-drug conjugate (1) suppresses anti-tumor immunity by promoting an increase in the expression level of PD-L1 on cancer cells, and is used in combination with PD-1 antibody. It is considered that the inhibitory signal is released and a stronger antitumor effect is exhibited.
- Dead cells were stained with LIVE / DEAD Fixable Near-IR Dead Cell Stain Kit purchased from Thermo Fisher Scientific and excluded from the analysis.
- the mean fluorescence intensity (MFI) of MHC class I was calculated, and the value obtained by subtracting the MFI in the cells treated with Isotype control from the MFI in the stained cells was defined as adjusted MFI.
- Comparison between the control group and the compound (A) group was performed by Dunnett's test, P value was described with 4 digits after the decimal point, and P ⁇ 0.05 (two-sided test) was considered significant.
- the results are shown in FIG. It was confirmed that the expression level of MHC class I on CT26.WT-hHER2 cells was significantly increased by the compound (A) (FIG. 17). Therefore, it was suggested that Compound (A) activates antitumor immunity by promoting an increase in the expression level of MHC class I on cancer cells.
- Antibody-drug conjugate (1) was administered via the tail vein at a dose of 10 mL / kg.
- CT26.WT-hHER2 cells were suspended in physiological saline, 5.0 ⁇ 10 6 cells were subcutaneously transplanted into the right axilla of BALB / c-nu mice, and grouped randomly after 3 days (Day 0) .
- the antibody-drug conjugate (1) was administered at a dose of 10 mg / kg twice a day on Days 0 and 7 by tail vein.
- a group to which the solvent of the antibody-drug conjugate (1) was administered was set as a control group. The number of mice in each group was 12, and the tumor volume was measured until Day 13.
- the results are shown in FIG.
- the vertical axis represents the tumor volume (mm 3 ), and the horizontal axis represents the number of days from the first administration day.
- the antitumor effect of the antibody-drug conjugate (1) administration observed in BALB / c mice was not observed in BALB / c-nu.
- BALB / c-nu the number of T-cells and B-cells is reduced and their functions are impaired, so these cells play an important role in the antitumor effect of the antibody-drug conjugate (1). It was thought to be responsible.
- mice in each group were 10, and the tumor volume was measured until Day 10.
- Comparison of the efficacy of the control antibody-drug conjugate group and the antibody-drug conjugate (1) group was performed using Wilcoxon rank sum test. P value was described with 4 digits after the decimal point, and P ⁇ 0.05 (two-sided test) was considered significant.
- the results are shown in FIG.
- the vertical axis represents the tumor volume (mm 3 ), and the horizontal axis represents the number of days from the first administration day.
- EMT6-hHER2 cells were implanted subcutaneously in the same manner as in Evaluation Example 1 for the single agent administration group and combination group of antibody-drug conjugate (1) and anti-PD-1 antibody (clone RMP1-14) The transition of tumor volume was measured.
- EMT6-hHER2 cells were prepared by introducing the human HER2 gene into a mouse breast cancer cell line EMT6 (CRL-2755) purchased from American Type Culture Collection using a lentiviral vector. These cells express human HER2 protein on the cell membrane.
- EMT6-hHER2 cells were suspended in physiological saline, 1.0 ⁇ 10 6 cells were subcutaneously transplanted into the right axilla of 5-week-old BALB / c mice, and grouped randomly at 4 days after transplantation (Day 0 ).
- Antibody-drug conjugate (1) was administered into the tail vein once a day 0 at a dose of 10 mg / kg.
- Anti-PD-1 antibody (clone RMP1-14) was prepared with D-PBS ( ⁇ ) (WAKO) and administered into the tail vein four times on Days 0, 3, 7, and 10 at a dose of 5.0 mg / kg.
- Dunnet's comparison of the efficacy of the control group with the antibody-drug conjugate (1) group and the anti-PD-1 antibody group, and the comparison of the efficacy of the antibody-drug conjugate (1) and anti-PD-1 antibody group with the two-drug combination group The test was performed using a multigroup comparison. The multiplicity-adjusted P value was described with 4 digits after the decimal point, and P ⁇ 0.05 (two-sided test) was considered significant.
- the results are shown in FIG.
- the vertical axis represents the tumor volume (mm 3 ), and the horizontal axis represents the number of days from the first administration day.
- the antibody-drug conjugate (1) group showed a significantly superior antitumor effect (P ⁇ 0.0001) compared to the control group.
- the anti-PD-1 antibody group showed a significantly superior antitumor effect (P ⁇ 0.0001).
- no weight loss of mice was observed in all groups in this study. Based on the above, the antitumor effect of single administration of both drugs was confirmed, and it was confirmed that the effect was dramatically enhanced by the combined use of two drugs.
- Anti-PD-L1 antibody was administered at a dose of 5 mg / kg twice a day on Days 0 and 3 in the tail vein.
- the day when the estimated tumor volume exceeded 3000 mm 3 (the day of euthanasia) was taken as the event occurrence day (the day of death), and the survival time of the control group, antibody-drug conjugate (1) group and anti-PD-L1 antibody group Comparison of the survival time of the antibody-drug conjugate (1) group, the anti-PD-L1 antibody group, and the both-drug combination group was performed using the Kaplan-Meier method / log rank test (multi-group comparison). The multiplicity-adjusted P value was described with 4 digits after the decimal point, and P ⁇ 0.05 (two-sided test) was considered significant.
- no weight loss of mice was observed in all groups in this study. Based on the above, the antitumor effect of single administration of both drugs was confirmed, and it was confirmed that the effect was enhanced by the combined use of two drugs.
- EMT6-hHER2 cells were subcutaneously transplanted into mice in the same manner as in Evaluation Example 11, and the antibody-drug conjugate (1) and anti-PD-L1 antibody single agent administration group and combination group were evaluated in the same manner as in Evaluation Example 12. The life-prolonging effect was measured. Grouping was performed randomly 5 days after the transplantation (Day 0), and the antibody-drug conjugate (1) was administered into the tail vein once a day 0 at a dose of 10 mg / kg. Anti-PD-L1 antibody was administered at a dose of 5 mg / kg twice a day on Days 0 and 3 in the tail vein.
- Antibody-drug conjugate (1) 10 mg / kg, depletion anti-CD4 antibody (Bio X Cell, clone GK1.5) and anti-CD8 antibody (Bio X Cell, clone 53.6.7) immediately before administration was prepared to 1 mg / mL using D-PBS (-) and administered to the mice at 200 ⁇ g / head on days 0 and 7 via the tail vein.
- a group in which a dedicated solvent for the antibody-drug conjugate (1) was administered was set. Grouping was performed on the fifth day (Day 0) after transplantation, and the tumor volume was measured until Day 11.
- the results are shown in FIGS.
- the tumor volume of the antibody-drug conjugate (1) group on Day 11 was 651 mm 3
- the antibody-drug conjugate (1) and anti-CD4 antibody combination group was 561 mm 3 . It was considered that CD4 positive cells did not contribute to the antitumor effect (FIG. 23).
- the tumor volume of the antibody-drug conjugate (1) group on Day 11 was 651 mm 3
- the antibody-drug conjugate (1) and anti-CD8 antibody combination group was 2247 mm 3 . It was considered that CD8 positive cells contributed to the antitumor effect (FIG. 24).
- the tumor growth curve is interrupted at the time of euthanasia.
- T cells or B cells are involved in part of the drug efficacy of the antibody-drug conjugate (1).
- CD8-positive T cells contribute to the antitumor effect of the antibody-drug conjugate (1).
- Dead cells were stained with LIVE / DEAD Fixable Near-IR Dead Cell Stain Kit purchased from Thermo Fisher Scientific and excluded from the analysis.
- the comparison between the control group and the antibody-drug conjugate (1) group was performed by Student's t-test, P value was described in 4 digits after the decimal point, and P ⁇ 0.05 (two-sided test) was considered significant.
- Anti-CTLA-4 antibody (clone 9H10) was purchased from Bio X Cell and diluted with D-PBS (-). Grouping was performed on the fifth day after transplantation (Day 0).
- Antibody-drug conjugate (1) was administered into the tail vein once a day 0 at a dose of 10 mg / kg.
- Anti-CTLA-4 antibody was administered at a dose of 5.0 mg / kg three days in days 0, 3 and 7 in the tail vein.
- the results are shown in FIG.
- the vertical axis represents the tumor volume (mm 3 ), and the horizontal axis represents the number of days from the first administration day.
- the antibody-drug conjugate according to the present invention exhibits a remarkably excellent antitumor effect when administered in combination with an immune checkpoint inhibitor. Further, it was shown that the antibody-drug conjugate according to the present invention has an effect of activating antitumor immunity. Thereby, the pharmaceutical composition and treatment method which are excellent in an anti-tumor effect and a safety surface can be provided.
- SEQ ID NO: 1 amino acid sequence of humanized anti-HER2 antibody heavy chain
- SEQ ID NO: 2 amino acid sequence of humanized anti-HER2 antibody light chain
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
[1]
抗体-薬物コンジュゲートと、免疫チェックポイント阻害剤が、組み合わされて投与されることを特徴とする医薬組成物であって、
該抗体-薬物コンジュゲートは、式
で示される薬物リンカーと、抗体とがチオエーテル結合によって結合した抗体-薬物コンジュゲートである、医薬組成物。
[2]
抗体-薬物コンジュゲートにおける抗体が、抗HER2抗体、抗HER3抗体、抗TROP2抗体、又は抗B7-H3抗体である、[1]に記載の医薬組成物。
[3]
抗体-薬物コンジュゲートにおける抗体が、抗HER2抗体である、[2]に記載の医薬組成物。
[4]
抗HER2抗体が、配列番号1においてアミノ酸番号1乃至449に記載のアミノ酸配列からなる重鎖及び配列番号2においてアミノ酸番号1乃至214に記載のアミノ酸配列からなる軽鎖を含んでなる抗体である、[2]又は[3]に記載の医薬組成物。
[5]
抗HER2抗体が、配列番号1に記載のアミノ酸配列からなる重鎖及び配列番号2に記載のアミノ酸配列からなる軽鎖を含んでなる抗体である、[2]又は[3]に記載の医薬組成物。
[6]
抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が2から8個の範囲である、[1]から[5]のいずれか1項に記載の医薬組成物。
[7]
抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が7から8個の範囲である、[1]から[5]のいずれか1項に記載の医薬組成物。
[8]
抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が7.5から8個の範囲である、[1]から[5]のいずれか1項に記載の医薬組成物。
[9]
免疫チェックポイント阻害剤が、抗PD-1抗体、抗PD-L1抗体、又は抗CTLA-4抗体である、[1]から[8]のいずれか1項に記載の医薬組成物。
[10]
免疫チェックポイント阻害剤が、抗PD-1抗体である、[9]に記載の医薬組成物。
[11]
免疫チェックポイント阻害剤が、抗PD-L1抗体である、[9]に記載の医薬組成物。
[12]
免疫チェックポイント阻害剤が、抗CTLA-4抗体である、[9]に記載の医薬組成物。
[13]
抗体-薬物コンジュゲートと、免疫チェックポイント阻害剤が、それぞれ別異の製剤に有効成分として含有され、同時に又は異なる時間に投与されることを特徴とする、[1]から[12]のいずれか1項に記載の医薬組成物。
[14]
抗体-薬物コンジュゲートと、免疫チェックポイント阻害剤が、単一の製剤に有効成分として含有され、投与されることを特徴とする、[1]から[12]のいずれか1項に記載の医薬組成物。
[15]
がんの治療のための、[1]から[14]のいずれか1項に記載の医薬組成物。
[16]
がんが、肺癌、尿路上皮癌、大腸癌、前立腺癌、卵巣癌、膵癌、乳癌、膀胱癌、胃癌、胃食道接合部腺癌、胃腸間質腫瘍、子宮頸癌、食道癌、扁平上皮癌、腹膜癌、肝臓癌、肝細胞癌、子宮内膜癌、子宮癌、唾液腺癌、腎臓癌、外陰部癌、甲状腺癌、陰茎癌、白血病、悪性リンパ腫、形質細胞腫、骨髄腫、神経上皮組織性腫瘍、神経鞘性腫瘍、頭頸部癌、皮膚癌、咽頭癌、胆のう癌、胆管癌、中皮腫、ページェット病、及び肉腫からなる群より選択される少なくとも一つである、[15]に記載の医薬組成物。
[17]
がんが大腸癌である、[16]に記載の医薬組成物。
[18]
がんが乳癌である、[16]に記載の医薬組成物。
[19]
抗体-薬物コンジュゲートが、抗腫瘍免疫を活性化する作用を有する、[1]から[18]のいずれか1項に記載の医薬組成物。
[20]
抗体-薬物コンジュゲートが、
(1)腫瘍内CD8陽性T細胞の増加を促進する作用、及び、
(2)腫瘍内CD8陽性T細胞を活性化する作用、
からなる群より選択される少なくとも一つの作用を有する、[1]から[19]のいずれか1項に記載の医薬組成物。
[21]
抗体-薬物コンジュゲートが、腫瘍に対する免疫記憶形成を促進する作用を有する、[1]から[20]のいずれか1項に記載の医薬組成物。
[22]
腫瘍が、抗体-薬物コンジュゲートにおける抗体に対する抗原を発現している、[21]に記載の医薬組成物。
[23]
腫瘍の一部が、抗体-薬物コンジュゲートにおける抗体に対する抗原を発現していない、[21]に記載の医薬組成物。
[24]
抗体-薬物コンジュゲートが、
(1)腫瘍内の樹状細胞数の増加を促進する作用、
(2)樹状細胞を活性化する作用、及び、
(3)がん細胞上のMHC class I発現量の増加を促進する作用、
からなる群より選択される少なくとも一つの作用を有する、[1]から[23]のいずれか1項に記載の医薬組成物。
[25]
抗体-薬物コンジュゲートが、がん細胞上のPD-L1発現量の増加を促進することにより生じた免疫抑制性シグナルを、免疫チェックポイント阻害剤が解除することにより、該抗体-薬物コンジュゲートがより強い抗腫瘍効果を示すことを特徴とする、[1]から[24]のいずれか1項に記載の医薬組成物。
[26]
式
で示される薬物リンカーと、抗体とがチオエーテル結合によって結合した抗体-薬物コンジュゲートを含有する、抗腫瘍免疫を活性化する作用により改善される疾患の治療に用いることを特徴とする医薬組成物。
[27]
抗体-薬物コンジュゲートが、
(1)腫瘍内CD8陽性T細胞の増加を促進する作用、及び、
(2)腫瘍内CD8陽性T細胞を活性化する作用、
からなる群より選択される少なくとも一つの作用を有する、[26]に記載の医薬組成物。
[28]
抗体-薬物コンジュゲートが、腫瘍に対する免疫記憶形成を促進する作用を有する、[26]又は[27]に記載の医薬組成物。
[29]
腫瘍が、抗体-薬物コンジュゲートにおける抗体に対する抗原を発現している、請求項[28]に記載の医薬組成物。
[30]
腫瘍の一部が、抗体-薬物コンジュゲートにおける抗体に対する抗原を発現していない、[28]に記載の医薬組成物。
[31]
抗体-薬物コンジュゲートが、
(1)腫瘍内の樹状細胞数の増加を促進する作用、
(2)樹状細胞を活性化する作用、及び、
(3)がん細胞上のMHC class I発現量の増加を促進する作用、
からなる群より選択される少なくとも一つの作用を有する、[26]から[30]のいずれか1項に記載の医薬組成物。
[32]
抗体-薬物コンジュゲートにおける抗体が、抗HER2抗体、抗HER3抗体、抗TROP2抗体、又は抗B7-H3抗体である、[26]から[31]のいずれか1項に記載の医薬組成物。
[33]
抗体-薬物コンジュゲートにおける抗体が、抗HER2抗体である、[32]に記載の医薬組成物。
[34]
抗HER2抗体が、配列番号1においてアミノ酸番号1乃至449に記載のアミノ酸配列からなる重鎖及び配列番号2においてアミノ酸番号1乃至214に記載のアミノ酸配列からなる軽鎖を含んでなる抗体である、[32]又は[33]に記載の医薬組成物。
[35]
抗HER2抗体が、配列番号1に記載のアミノ酸配列からなる重鎖及び配列番号2に記載のアミノ酸配列からなる軽鎖を含んでなる抗体である、[32]又は[33]に記載の医薬組成物。
[36]
抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が2から8個の範囲である、[26]から[35]のいずれか1項に記載の医薬組成物。
[37]
抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が7から8個の範囲である、[26]から[35]のいずれか1項に記載の医薬組成物。
[38]
抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が7.5から8個の範囲である、[26]から[35]のいずれか1項に記載の医薬組成物。
[39]
疾患が、肺癌、尿路上皮癌、大腸癌、前立腺癌、卵巣癌、膵癌、乳癌、膀胱癌、胃癌、胃食道接合部腺癌、胃腸間質腫瘍、子宮頸癌、食道癌、扁平上皮癌、腹膜癌、肝臓癌、肝細胞癌、子宮内膜癌、子宮癌、唾液腺癌、腎臓癌、外陰部癌、甲状腺癌、陰茎癌、白血病、悪性リンパ腫、形質細胞腫、骨髄腫、神経上皮組織性腫瘍、神経鞘性腫瘍、頭頸部癌、皮膚癌、咽頭癌、胆のう癌、胆管癌、中皮腫、ページェット病、及び肉腫からなる群より選択される少なくとも一つである、[26]から[38]のいずれか1項に記載の医薬組成物。
[40]
疾患が大腸癌である、[39]に記載の医薬組成物。
[41]
疾患が乳癌である、[39]に記載の医薬組成物。
[42]
式
[43]
化合物が、
(1)腫瘍内CD8陽性T細胞の増加を促進する作用、及び、
(2)腫瘍内CD8陽性T細胞を活性化する作用、
からなる群より選択される少なくとも一つの作用を有する、[42]に記載の医薬組成物。
[44]
化合物が、腫瘍に対する免疫記憶形成を促進する作用を有する、[42]又は[43]に記載の医薬組成物。
[45]
化合物が、
(1)腫瘍内の樹状細胞数の増加を促進する作用、
(2)樹状細胞を活性化する作用、及び、
(3)がん細胞上のMHC class I発現量の増加を促進する作用、
からなる群より選択される少なくとも一つの作用を有する、[42]から[44]のいずれか1項に記載の医薬組成物。
[46]
疾患が、肺癌、尿路上皮癌、大腸癌、前立腺癌、卵巣癌、膵癌、乳癌、膀胱癌、胃癌、胃食道接合部腺癌、胃腸間質腫瘍、子宮頸癌、食道癌、扁平上皮癌、腹膜癌、肝臓癌、肝細胞癌、子宮内膜癌、子宮癌、唾液腺癌、腎臓癌、外陰部癌、甲状腺癌、陰茎癌、白血病、悪性リンパ腫、形質細胞腫、骨髄腫、神経上皮組織性腫瘍、神経鞘性腫瘍、頭頸部癌、皮膚癌、咽頭癌、胆のう癌、胆管癌、中皮腫、ページェット病、及び肉腫からなる群より選択される少なくとも一つである、[42]から[45]のいずれか1項に記載の医薬組成物。
[47]
抗体-薬物コンジュゲートと、免疫チェックポイント阻害剤が、組み合わされて投与されることを特徴とする治療方法であって、
該抗体-薬物コンジュゲートは、式
で示される薬物リンカーと、抗体とがチオエーテル結合によって結合した抗体-薬物コンジュゲートである、治療方法。
[48]
抗体-薬物コンジュゲートにおける抗体が、抗HER2抗体、抗HER3抗体、抗TROP2抗体、又は抗B7-H3抗体である、[47]に記載の治療方法。
[49]
抗体-薬物コンジュゲートにおける抗体が、抗HER2抗体である、[48]に記載の治療方法。
[50]
抗HER2抗体が、配列番号1においてアミノ酸番号1乃至449に記載のアミノ酸配列からなる重鎖及び配列番号2においてアミノ酸番号1乃至214に記載のアミノ酸配列からなる軽鎖を含んでなる抗体である、[48]又は[49]に記載の治療方法。
[51]
抗HER2抗体が、配列番号1に記載のアミノ酸配列からなる重鎖及び配列番号2に記載のアミノ酸配列からなる軽鎖を含んでなる抗体である、[48]又は[49]に記載の治療方法。
[52]
抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が2から8個の範囲である、[47]から[51]のいずれか1項に記載の治療方法。
[53]
抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が7から8個の範囲である、[47]から[51]のいずれか1項に記載の治療方法。
[54]
抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が7.5から8個の範囲である、[47]から[51]のいずれか1項に記載の治療方法。
[55]
免疫チェックポイント阻害剤が、抗PD-1抗体、抗PD-L1抗体、又は抗CTLA-4抗体である、[47]から[54]のいずれか1項に記載の治療方法。
[56]
免疫チェックポイント阻害剤が、抗PD-1抗体である、[55]に記載の治療方法。
[57]
免疫チェックポイント阻害剤が、抗PD-L1抗体である、[55]に記載の治療方法。
[58]
免疫チェックポイント阻害剤が、抗CTLA-4抗体である、[55]に記載の治療方法。
[59]
抗体-薬物コンジュゲートと、免疫チェックポイント阻害剤が、それぞれ別異の製剤に有効成分として含有され、同時に又は異なる時間に投与されることを特徴とする、[47]から[58]のいずれか1項に記載の治療方法。
[60]
抗体-薬物コンジュゲートと、免疫チェックポイント阻害剤が、単一の製剤に有効成分として含有され、投与されることを特徴とする、[47]から[58]のいずれか1項に記載の治療方法。
[61]
がんの治療のための、[47]から[60]のいずれか1項に記載の治療方法。
[62]
がんが、肺癌、尿路上皮癌、大腸癌、前立腺癌、卵巣癌、膵癌、乳癌、膀胱癌、胃癌、胃食道接合部腺癌、胃腸間質腫瘍、子宮頸癌、食道癌、扁平上皮癌、腹膜癌、肝臓癌、肝細胞癌、子宮内膜癌、子宮癌、唾液腺癌、腎臓癌、外陰部癌、甲状腺癌、陰茎癌、白血病、悪性リンパ腫、形質細胞腫、骨髄腫、神経上皮組織性腫瘍、神経鞘性腫瘍、頭頸部癌、皮膚癌、咽頭癌、胆のう癌、胆管癌、中皮腫、ページェット病、及び肉腫からなる群より選択される少なくとも一つである、[61]に記載の治療方法。
[63]
がんが大腸癌である、[62]に記載の治療方法。
[64]
がんが乳癌である、[62]に記載の治療方法。
[65]
抗体-薬物コンジュゲートが、抗腫瘍免疫を活性化する作用を有する、[47]から[64]のいずれか1項に記載の治療方法。
[66]
抗体-薬物コンジュゲートが、
(1)腫瘍内CD8陽性T細胞の増加を促進する作用、及び、
(2)腫瘍内CD8陽性T細胞を活性化する作用、
からなる群より選択される少なくとも一つの作用を有する、[47]から[65]のいずれか1項に記載の医薬組成物。
[67]
抗体-薬物コンジュゲートが、腫瘍に対する免疫記憶形成を促進する作用を有する、[47]から[66]のいずれか1項に記載の治療方法。
[68]
腫瘍が、抗体-薬物コンジュゲートにおける抗体に対する抗原を発現している、[67]に記載の治療方法。
[69]
腫瘍の一部が、抗体-薬物コンジュゲートにおける抗体に対する抗原を発現していない、[67]に記載の治療方法。
[70]
抗体-薬物コンジュゲートが、
(1)腫瘍内の樹状細胞数の増加を促進する作用、
(2)樹状細胞を活性化する作用、及び、
(3)がん細胞上のMHC class I発現量の増加を促進する作用、
からなる群より選択される少なくとも一つの作用を有する、[47]から[69]のいずれか1項に記載の治療方法。
[71]
抗体-薬物コンジュゲートが、がん細胞上のPD-L1発現量の増加を促進することにより生じた免疫抑制性シグナルを、免疫チェックポイント阻害剤が解除することにより、該抗体-薬物コンジュゲートがより強い抗腫瘍効果を示すことを特徴とする、[47]から[70]のいずれか1項に記載の治療方法。
[72]
式
で示される薬物リンカーと、抗体とがチオエーテル結合によって結合した抗体-薬物コンジュゲートを投与する、抗腫瘍免疫を活性化する作用により改善される疾患に対して用いることを特徴とする治療方法。
[73]
抗体-薬物コンジュゲートが、
(1)腫瘍内CD8陽性T細胞の増加を促進する作用、及び、
(2)腫瘍内CD8陽性T細胞を活性化する作用、
からなる群より選択される少なくとも一つの作用を有する、[72]に記載の治療方法。
[74]
抗体-薬物コンジュゲートが、腫瘍に対する免疫記憶形成を促進する作用を有する、[72]又は[73]に記載の治療方法。
[75]
腫瘍が、抗体-薬物コンジュゲートにおける抗体に対する抗原を発現している、[74]に記載の治療方法。
[76]
腫瘍の一部が、抗体-薬物コンジュゲートにおける抗体に対する抗原を発現していない、[74]に記載の治療方法。
[77]
抗体-薬物コンジュゲートが、
(1)腫瘍内の樹状細胞数の増加を促進する作用、
(2)樹状細胞を活性化する作用、及び、
(3)がん細胞上のMHC class I発現量の増加を促進する作用、
からなる群より選択される少なくとも一つの作用を有する、[72]から[76]のいずれか1項に記載の治療方法。
[78]
抗体-薬物コンジュゲートにおける抗体が、抗HER2抗体、抗HER3抗体、抗TROP2抗体、又は抗B7-H3抗体である、[72]から[77]のいずれか1項に記載の治療方法。
[79]
抗体-薬物コンジュゲートにおける抗体が、抗HER2抗体である、[78]に記載の治療方法。
[80]
抗HER2抗体が、配列番号1においてアミノ酸番号1乃至449に記載のアミノ酸配列からなる重鎖及び配列番号2においてアミノ酸番号1乃至214に記載のアミノ酸配列からなる軽鎖を含んでなる抗体である、[78]又は[79]に記載の治療方法。
[81]
抗HER2抗体が、配列番号1に記載のアミノ酸配列からなる重鎖及び配列番号2に記載のアミノ酸配列からなる軽鎖を含んでなる抗体である、[78]又は[79]に記載の治療方法。
[82]
抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が2から8個の範囲である、[72]から[81]のいずれか1項に記載の治療方法。
[83]
抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が7から8個の範囲である、[72]から[81]のいずれか1項に記載の治療方法。
[84]
抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が7.5から8個の範囲である、[72]から[81]のいずれか1項に記載の治療方法。
[85]
疾患が、肺癌、尿路上皮癌、大腸癌、前立腺癌、卵巣癌、膵癌、乳癌、膀胱癌、胃癌、胃食道接合部腺癌、胃腸間質腫瘍、子宮頸癌、食道癌、扁平上皮癌、腹膜癌、肝臓癌、肝細胞癌、子宮内膜癌、子宮癌、唾液腺癌、腎臓癌、外陰部癌、甲状腺癌、陰茎癌、白血病、悪性リンパ腫、形質細胞腫、骨髄腫、神経上皮組織性腫瘍、神経鞘性腫瘍、頭頸部癌、皮膚癌、咽頭癌、胆のう癌、胆管癌、中皮腫、ページェット病、及び肉腫からなる群より選択される少なくとも一つである、[72]から[84]のいずれか1項に記載の治療方法。
[86]
疾患が大腸癌である、[85]に記載の治療方法。
[87]
疾患が乳癌である、[85]に記載の治療方法。
[88]
式
[89]
化合物が、
(1)腫瘍内CD8陽性T細胞の増加を促進する作用、及び、
(2)腫瘍内CD8陽性T細胞を活性化する作用、
からなる群より選択される少なくとも一つの作用を有する、[88]に記載の治療方法。
[90]
化合物が、腫瘍に対する免疫記憶形成を促進する作用を有する、[88]又は[89]に記載の治療方法。
[91]
化合物が、
(1)腫瘍内の樹状細胞数の増加を促進する作用、
(2)樹状細胞を活性化する作用、及び、
(3)がん細胞上のMHC class I発現量の増加を促進する作用、
からなる群より選択される少なくとも一つの作用を有する、[88]から[90]のいずれか1項に記載の治療方法。
[92]
疾患が、肺癌、尿路上皮癌、大腸癌、前立腺癌、卵巣癌、膵癌、乳癌、膀胱癌、胃癌、胃食道接合部腺癌、胃腸間質腫瘍、子宮頸癌、食道癌、扁平上皮癌、腹膜癌、肝臓癌、肝細胞癌、子宮内膜癌、子宮癌、唾液腺癌、腎臓癌、外陰部癌、甲状腺癌、陰茎癌、白血病、悪性リンパ腫、形質細胞腫、骨髄腫、神経上皮組織性腫瘍、神経鞘性腫瘍、頭頸部癌、皮膚癌、咽頭癌、胆のう癌、胆管癌、中皮腫、ページェット病、及び肉腫からなる群より選択される少なくとも一つである、[88]から[91]のいずれか1項に記載の治療方法。
[93]
免疫チェックポイント阻害剤と、組み合わされて投与されることにより、疾患を治療するための
式
で示される薬物リンカーと、抗体とがチオエーテル結合によって結合した抗体-薬物コンジュゲート。
[94]
抗体-薬物コンジュゲートにおける抗体が、抗HER2抗体、抗HER3抗体、抗TROP2抗体、又は抗B7-H3抗体である、[93]に記載の抗体-薬物コンジュゲート。
[95]
抗体-薬物コンジュゲートにおける抗体が、抗HER2抗体である、[94]に記載の抗体-薬物コンジュゲート。
[96]
抗HER2抗体が、配列番号1においてアミノ酸番号1乃至449に記載のアミノ酸配列からなる重鎖及び配列番号2においてアミノ酸番号1乃至214に記載のアミノ酸配列からなる軽鎖を含んでなる抗体である、[94]又は[95]に記載の抗体-薬物コンジュゲート。
[97]
抗HER2抗体が、配列番号1に記載のアミノ酸配列からなる重鎖及び配列番号2に記載のアミノ酸配列からなる軽鎖を含んでなる抗体である、[94]又は[95]に記載の抗体-薬物コンジュゲート。
[98]
抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が2から8個の範囲である、[93]から[97]のいずれか1項に記載の抗体-薬物コンジュゲート。
[99]
抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が7から8個の範囲である、[93]から[97]のいずれか1項に記載の抗体-薬物コンジュゲート。
[100]
抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が7.5から8個の範囲である、[93]から[97]のいずれか1項に記載の抗体-薬物コンジュゲート。
[101]
免疫チェックポイント阻害剤が、抗PD-1抗体、抗PD-L1抗体、又は抗CTLA-4抗体である、[93]から[100]のいずれか1項に記載の抗体-薬物コンジュゲート。
[102]
免疫チェックポイント阻害剤が、抗PD-1抗体である、[101]に記載の抗体-薬物コンジュゲート。
[103]
免疫チェックポイント阻害剤が、抗PD-L1抗体である、[101]に記載の抗体-薬物コンジュゲート。
[104]
免疫チェックポイント阻害剤が、抗CTLA-4抗体である、[101]に記載の抗体-薬物コンジュゲート。
[105]
抗体-薬物コンジュゲートと、免疫チェックポイント阻害剤が、それぞれ別異の製剤に有効成分として含有され、同時に又は異なる時間に投与されることを特徴とする、[93]から[104]のいずれか1項に記載の抗体-薬物コンジュゲート。
[106]
抗体-薬物コンジュゲートと、免疫チェックポイント阻害剤が、単一の製剤に有効成分として含有され、投与されることを特徴とする、[93]から[104]のいずれか1項に記載の抗体-薬物コンジュゲート。
[107]
がんの治療のための、[93]から[106]のいずれか1項に記載の抗体-薬物コンジュゲート。
[108]
がんが、肺癌、尿路上皮癌、大腸癌、前立腺癌、卵巣癌、膵癌、乳癌、膀胱癌、胃癌、胃食道接合部腺癌、胃腸間質腫瘍、子宮頸癌、食道癌、扁平上皮癌、腹膜癌、肝臓癌、肝細胞癌、子宮内膜癌、子宮癌、唾液腺癌、腎臓癌、外陰部癌、甲状腺癌、陰茎癌、白血病、悪性リンパ腫、形質細胞腫、骨髄腫、神経上皮組織性腫瘍、神経鞘性腫瘍、頭頸部癌、皮膚癌、咽頭癌、胆のう癌、胆管癌、中皮腫、ページェット病、及び肉腫からなる群より選択される少なくとも一つである、[107]に記載の抗体-薬物コンジュゲート。
[109]
がんが大腸癌である、[108]に記載の抗体-薬物コンジュゲート。
[110]
がんが乳癌である、[108]に記載の抗体-薬物コンジュゲート。
[111]
抗腫瘍免疫を活性化する作用を有する、[93]から[110]のいずれか1項に記載の抗体-薬物コンジュゲート。
[112]
(1)腫瘍内CD8陽性T細胞の増加を促進する作用、及び、
(2)腫瘍内CD8陽性T細胞を活性化する作用、
からなる群より選択される少なくとも一つの作用を有する、[93]から[111]のいずれか1項に記載の抗体-薬物コンジュゲート。
[113]
腫瘍に対する免疫記憶形成を促進する作用を有する、[93]から[112]のいずれか1項に記載の抗体-薬物コンジュゲート。
[114]
腫瘍が、抗体-薬物コンジュゲートにおける抗体に対する抗原を発現している、[113]に記載の抗体-薬物コンジュゲート。
[115]
腫瘍の一部が、抗体-薬物コンジュゲートにおける抗体に対する抗原を発現していない、[113]に記載の抗体-薬物コンジュゲート。
[116]
(1)腫瘍内の樹状細胞数の増加を促進する作用、
(2)樹状細胞を活性化する作用、及び、
(3)がん細胞上のMHC class I発現量の増加を促進する作用、
からなる群より選択される少なくとも一つの作用を有する、[93]から[115]のいずれか1項に記載の抗体-薬物コンジュゲート。
[117]
がん細胞上のPD-L1発現量の増加を促進することにより生じた免疫抑制性シグナルを、免疫チェックポイント阻害剤が解除することにより、該抗体-薬物コンジュゲートがより強い抗腫瘍効果を示すことを特徴とする、[93]から[116]のいずれか1項に記載の抗体-薬物コンジュゲート。
[118]
抗腫瘍免疫を活性化する作用により改善される疾患の治療に用いるための
式
で示される薬物リンカーと、抗体とがチオエーテル結合によって結合した抗体-薬物コンジュゲート。
[119]
(1)腫瘍内CD8陽性T細胞の増加を促進する作用、及び、
(2)腫瘍内CD8陽性T細胞を活性化する作用、
からなる群より選択される少なくとも一つの作用を有する、[118]に記載の抗体-薬物コンジュゲート。
[120]
腫瘍に対する免疫記憶形成を促進する作用を有する、[118]又は[119]に記載の抗体-薬物コンジュゲート。
[121]
腫瘍が、抗体-薬物コンジュゲートにおける抗体に対する抗原を発現している、請求項[120]に記載の抗体-薬物コンジュゲート。
[122]
腫瘍の一部が、抗体-薬物コンジュゲートにおける抗体に対する抗原を発現していない、[120]に記載の抗体-薬物コンジュゲート。
[123]
(1)腫瘍内の樹状細胞数の増加を促進する作用、
(2)樹状細胞を活性化する作用、及び、
(3)がん細胞上のMHC class I発現量の増加を促進する作用、
からなる群より選択される少なくとも一つの作用により改善される疾患の治療に用いるための[118]から[122]のいずれか1項に記載の抗体-薬物コンジュゲート。
[124]
抗体-薬物コンジュゲートにおける抗体が、抗HER2抗体、抗HER3抗体、抗TROP2抗体、又は抗B7-H3抗体である、[118]から[123]のいずれか1項に記載の抗体-薬物コンジュゲート。
[125]
抗体-薬物コンジュゲートにおける抗体が、抗HER2抗体である、[124]に記載の抗体-薬物コンジュゲート。
[126]
抗HER2抗体が、配列番号1においてアミノ酸番号1乃至449に記載のアミノ酸配列からなる重鎖及び配列番号2においてアミノ酸番号1乃至214に記載のアミノ酸配列からなる軽鎖を含んでなる抗体である、[124]又は[125]に記載の抗体-薬物コンジュゲート。
[127]
抗HER2抗体が、配列番号1に記載のアミノ酸配列からなる重鎖及び配列番号2に記載のアミノ酸配列からなる軽鎖を含んでなる抗体である、[124]又は[125]に記載の抗体-薬物コンジュゲート。
[128]
抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が2から8個の範囲である、[118]から[127]のいずれか1項に記載の抗体-薬物コンジュゲート。
[129]
抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が7から8個の範囲である、[118]から[127]のいずれか1項に記載の抗体-薬物コンジュゲート。
[130]
抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が7.5から8個の範囲である、[118]から[127]のいずれか1項に記載の抗体-薬物コンジュゲート。
[131]
疾患が、肺癌、尿路上皮癌、大腸癌、前立腺癌、卵巣癌、膵癌、乳癌、膀胱癌、胃癌、胃食道接合部腺癌、胃腸間質腫瘍、子宮頸癌、食道癌、扁平上皮癌、腹膜癌、肝臓癌、肝細胞癌、子宮内膜癌、子宮癌、唾液腺癌、腎臓癌、外陰部癌、甲状腺癌、陰茎癌、白血病、悪性リンパ腫、形質細胞腫、骨髄腫、神経上皮組織性腫瘍、神経鞘性腫瘍、頭頸部癌、皮膚癌、咽頭癌、胆のう癌、胆管癌、中皮腫、ページェット病、及び肉腫からなる群より選択される少なくとも一つである、[118]から[130]のいずれか1項に記載の抗体-薬物コンジュゲート。
[132]
疾患が大腸癌である、[131]に記載の抗体-薬物コンジュゲート。
[133]
疾患が乳癌である、[131]に記載の抗体-薬物コンジュゲート。
[134]
腫瘍内で放出されることにより、抗腫瘍免疫を活性化する作用により改善される疾患の治療に用いるための
式
[135]
(1)腫瘍内CD8陽性T細胞の増加を促進する作用、及び、
(2)腫瘍内CD8陽性T細胞を活性化する作用、
からなる群より選択される少なくとも一つの作用を有する、[134]に記載の化合物。
[136]
腫瘍に対する免疫記憶形成を促進する作用を有する、[134]又は[135]に記載の化合物。
[137]
(1)腫瘍内の樹状細胞数の増加を促進する作用、
(2)樹状細胞を活性化する作用、及び、
(3)がん細胞上のMHC class I発現量の増加を促進する作用、
からなる群より選択される少なくとも一つの作用を有する、[134]から[136]のいずれか1項に記載の化合物。
[138]
疾患が、肺癌、尿路上皮癌、大腸癌、前立腺癌、卵巣癌、膵癌、乳癌、膀胱癌、胃癌、胃食道接合部腺癌、胃腸間質腫瘍、子宮頸癌、食道癌、扁平上皮癌、腹膜癌、肝臓癌、肝細胞癌、子宮内膜癌、子宮癌、唾液腺癌、腎臓癌、外陰部癌、甲状腺癌、陰茎癌、白血病、悪性リンパ腫、形質細胞腫、骨髄腫、神経上皮組織性腫瘍、神経鞘性腫瘍、頭頸部癌、皮膚癌、咽頭癌、胆のう癌、胆管癌、中皮腫、ページェット病、及び肉腫からなる群より選択される少なくとも一つである、[134]から[137]のいずれか1項に記載の化合物。
[139]
免疫チェックポイント阻害剤と、組み合わされて投与されることにより、疾患を治療するための医薬の製造のための
式
で示される薬物リンカーと、抗体とがチオエーテル結合によって結合した抗体-薬物コンジュゲートの使用。
[140]
抗体-薬物コンジュゲートにおける抗体が、抗HER2抗体、抗HER3抗体、抗TROP2抗体、又は抗B7-H3抗体である、[139]に記載の使用。
[141]
抗体-薬物コンジュゲートにおける抗体が、抗HER2抗体である、[140]に記載の使用。
[142]
抗HER2抗体が、配列番号1においてアミノ酸番号1乃至449に記載のアミノ酸配列からなる重鎖及び配列番号2においてアミノ酸番号1乃至214に記載のアミノ酸配列からなる軽鎖を含んでなる抗体である、[140]又は[141]に記載の使用。
[143]
抗HER2抗体が、配列番号1に記載のアミノ酸配列からなる重鎖及び配列番号2に記載のアミノ酸配列からなる軽鎖を含んでなる抗体である、[140]又は[141]に記載の使用。
[144]
抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が2から8個の範囲である、[139]から[143]のいずれか1項に記載の使用。
[145]
抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が7から8個の範囲である、[139]から[143]のいずれか1項に記載の使用。
[146]
抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が7.5から8個の範囲である、[139]から[143]のいずれか1項に記載の使用。
[147]
免疫チェックポイント阻害剤が、抗PD-1抗体、抗PD-L1抗体、又は抗CTLA-4抗体である、[139]から[146]のいずれか1項に記載の使用。
[148]
免疫チェックポイント阻害剤が、抗PD-1抗体である、[147]に記載の使用。
[149]
免疫チェックポイント阻害剤が、抗PD-L1抗体である、[147]に記載の使用。
[150]
免疫チェックポイント阻害剤が、抗CTLA-4抗体である、[147]に記載の使用。
[151]
抗体-薬物コンジュゲートと、免疫チェックポイント阻害剤が、それぞれ別異の製剤に有効成分として含有され、同時に又は異なる時間に投与されることを特徴とする、[139]から[150]のいずれか1項に記載の使用。
[152]
抗体-薬物コンジュゲートと、免疫チェックポイント阻害剤が、単一の製剤に有効成分として含有され、投与されることを特徴とする、[139]から[150]のいずれか1項に記載の使用。
[153]
がんの治療のための、[139]から[152]のいずれか1項に記載の使用。
[154]
がんが、肺癌、尿路上皮癌、大腸癌、前立腺癌、卵巣癌、膵癌、乳癌、膀胱癌、胃癌、胃食道接合部腺癌、胃腸間質腫瘍、子宮頸癌、食道癌、扁平上皮癌、腹膜癌、肝臓癌、肝細胞癌、子宮内膜癌、子宮癌、唾液腺癌、腎臓癌、外陰部癌、甲状腺癌、陰茎癌、白血病、悪性リンパ腫、形質細胞腫、骨髄腫、神経上皮組織性腫瘍、神経鞘性腫瘍、頭頸部癌、皮膚癌、咽頭癌、胆のう癌、胆管癌、中皮腫、ページェット病、及び肉腫からなる群より選択される少なくとも一つである、[153]に記載の使用。
[155]
がんが大腸癌である、[154]に記載の使用。
[156]
がんが乳癌である、[154]に記載の使用。
[157]
抗体-薬物コンジュゲートが、抗腫瘍免疫を活性化する作用を有する、[139]から[156]のいずれか1項に記載の使用。
[158]
抗体-薬物コンジュゲートが、
(1)腫瘍内CD8陽性T細胞の増加を促進する作用、及び、
(2)腫瘍内CD8陽性T細胞を活性化する作用、
からなる群より選択される少なくとも一つの作用を有する、[139]から[157]のいずれか1項に記載の使用。
[159]
抗体-薬物コンジュゲートが、腫瘍に対する免疫記憶形成を促進する作用を有する、[139]から[158]のいずれか1項に記載の使用。
[160]
腫瘍が、抗体-薬物コンジュゲートにおける抗体に対する抗原を発現している、[159]に記載の使用。
[161]
腫瘍の一部が、抗体-薬物コンジュゲートにおける抗体に対する抗原を発現していない、[159]に記載の使用。
[162]
抗体-薬物コンジュゲートが、
(1)腫瘍内の樹状細胞数の増加を促進する作用、
(2)樹状細胞を活性化する作用、及び、
(3)がん細胞上のMHC class I発現量の増加を促進する作用、
からなる群より選択される少なくとも一つの作用を有する、[139]から[161]のいずれか1項に記載の使用。
[163]
抗体-薬物コンジュゲートが、がん細胞上のPD-L1発現量の増加を促進することにより生じた免疫抑制性シグナルを、免疫チェックポイント阻害剤が解除することにより、該抗体-薬物コンジュゲートがより強い抗腫瘍効果を示すことを特徴とする、[139]から[162]のいずれか1項に記載の使用。
[164]
抗腫瘍免疫を活性化する作用により改善される疾患の治療に用いることを特徴とする医薬の製造のための
式
で示される薬物リンカーと、抗体とがチオエーテル結合によって結合した抗体-薬物コンジュゲートの使用。
[165]
抗体-薬物コンジュゲートが、
(1)腫瘍内CD8陽性T細胞の増加を促進する作用、及び、
(2)腫瘍内CD8陽性T細胞を活性化する作用、
からなる群より選択される少なくとも一つの作用を有する、[164]に記載の使用。
[166]
抗体-薬物コンジュゲートが、腫瘍に対する免疫記憶形成を促進する作用を有する、[164]又は[165]に記載の使用。
[167]
腫瘍が、抗体-薬物コンジュゲートにおける抗体に対する抗原を発現している、請求項[166]に記載の使用。
[168]
腫瘍の一部が、抗体-薬物コンジュゲートにおける抗体に対する抗原を発現していない、[166]に記載の使用。
[169]
(1)腫瘍内の樹状細胞数の増加を促進する作用、
(2)樹状細胞を活性化する作用、及び、
(3)がん細胞上のMHC class I発現量の増加を促進する作用、
からなる群より選択される少なくとも一つの作用により改善される疾患の治療に用いるための医薬の製造のための[164]から[168]のいずれか1項に記載の使用。
[170]
抗体-薬物コンジュゲートにおける抗体が、抗HER2抗体、抗HER3抗体、抗TROP2抗体、又は抗B7-H3抗体である、[164]から[169]のいずれか1項に記載の使用。
[171]
抗体-薬物コンジュゲートにおける抗体が、抗HER2抗体である、[170]に記載の使用。
[172]
抗HER2抗体が、配列番号1においてアミノ酸番号1乃至449に記載のアミノ酸配列からなる重鎖及び配列番号2においてアミノ酸番号1乃至214に記載のアミノ酸配列からなる軽鎖を含んでなる抗体である、[170]又は[171]に記載の使用。
[173]
抗HER2抗体が、配列番号1に記載のアミノ酸配列からなる重鎖及び配列番号2に記載のアミノ酸配列からなる軽鎖を含んでなる抗体である、[170]又は[171]に記載の使用。
[174]
抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が2から8個の範囲である、[164]から[173]のいずれか1項に記載の使用。
[175]
抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が7から8個の範囲である、[164]から[173]のいずれか1項に記載の使用。
[176]
抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が7.5から8個の範囲である、[164]から[173]のいずれか1項に記載の使用。
[177]
疾患が、肺癌、尿路上皮癌、大腸癌、前立腺癌、卵巣癌、膵癌、乳癌、膀胱癌、胃癌、胃食道接合部腺癌、胃腸間質腫瘍、子宮頸癌、食道癌、扁平上皮癌、腹膜癌、肝臓癌、肝細胞癌、子宮内膜癌、子宮癌、唾液腺癌、腎臓癌、外陰部癌、甲状腺癌、陰茎癌、白血病、悪性リンパ腫、形質細胞腫、骨髄腫、神経上皮組織性腫瘍、神経鞘性腫瘍、頭頸部癌、皮膚癌、咽頭癌、胆のう癌、胆管癌、中皮腫、ページェット病、及び肉腫からなる群より選択される少なくとも一つである、[164]から[176]のいずれか1項に記載の使用。
[178]
疾患が大腸癌である、[177]に記載の使用。
[179]
疾患が乳癌である、[177]に記載の使用。
[180]
式
[181]
化合物が、
(1)腫瘍内CD8陽性T細胞の増加を促進する作用、及び、
(2)腫瘍内CD8陽性T細胞を活性化する作用、
からなる群より選択される少なくとも一つの作用を有する、[180]に記載の使用。
[182]
化合物が、腫瘍に対する免疫記憶形成を促進する作用を有する、[180]又は[181]に記載の使用。
[183]
化合物が、
(1)腫瘍内の樹状細胞数の増加を促進する作用、
(2)樹状細胞を活性化する作用、及び、
(3)がん細胞上のMHC class I発現量の増加を促進する作用、
からなる群より選択される少なくとも一つの作用を有する、[180]から[182]のいずれか1項に記載の使用。
[184]
疾患が、肺癌、尿路上皮癌、大腸癌、前立腺癌、卵巣癌、膵癌、乳癌、膀胱癌、胃癌、胃食道接合部腺癌、胃腸間質腫瘍、子宮頸癌、食道癌、扁平上皮癌、腹膜癌、肝臓癌、肝細胞癌、子宮内膜癌、子宮癌、唾液腺癌、腎臓癌、外陰部癌、甲状腺癌、陰茎癌、白血病、悪性リンパ腫、形質細胞腫、骨髄腫、神経上皮組織性腫瘍、神経鞘性腫瘍、頭頸部癌、皮膚癌、咽頭癌、胆のう癌、胆管癌、中皮腫、ページェット病、及び肉腫からなる群より選択される少なくとも一つである、[180]から[183]のいずれか1項に記載の使用。
本発明において使用される抗体-薬物コンジュゲートは、式
で示される薬物リンカーと、抗体とがチオエーテル結合によって結合した抗体-薬物コンジュゲートである。
(1)腫瘍内CD8陽性T細胞の増加を促進する作用、及び、
(2)腫瘍内CD8陽性T細胞を活性化する作用、
からなる群より選択される少なくとも一つの作用を有する。
(1)腫瘍内の樹状細胞数の増加を促進する作用、
(2)樹状細胞を活性化する作用、及び、
(3)がん細胞上のMHC class I発現量の増加を促進する作用、
からなる群より選択される少なくとも一つの作用を有する。
これらの作用は、上述の「腫瘍に対する免疫記憶形成を促進する作用」に寄与し、ひいては上述の「抗腫瘍免疫を活性化する作用」に寄与する。
(1)腫瘍内の樹状細胞数の増加を促進する作用、
(2)樹状細胞を活性化する作用、及び、
(3)がん細胞上のMHC class I発現量の増加を促進する作用、
からなる群より選択される少なくとも一つの作用を有することが期待される。
(1)腫瘍内CD8陽性T細胞の増加を促進する作用、及び、
(2)腫瘍内CD8陽性T細胞を活性化する作用、
からなる群より選択される少なくとも一つの作用を有することが期待され、
ひいては、「抗腫瘍免疫を活性化する作用」を有することが期待される。
このバイスタンダー効果は、本発明で使用される抗体-薬物コンジュゲートが、標的発現がん細胞に内在化した後、放出された化合物(A)が、標的を発現していない近傍のがん細胞に対しても抗腫瘍効果を及ぼすことにより発揮される。
本発明で使用される抗体-薬物コンジュゲートが有するバイスタンダー効果は、免疫チェックポイント阻害剤と組み合わせて使用する場合においても、優れた抗腫瘍効果として発揮される。
[抗体-薬物コンジュゲートの製造に使用される抗体]
本発明に係る抗体-薬物コンジュゲートの製造に使用される抗体は、いずれの種に由来してもよいが、好適には、ヒト、ラット、マウス、及びウサギに由来する抗体である。抗体がヒト以外の種に由来する場合は、周知の技術を用いて、キメラ化又はヒト化することが好ましい。本発明の抗体は、ポリクローナル抗体であっても、モノクローナル抗体であってもよいが、モノクローナル抗体が好ましい。
(1)配列番号1においてアミノ酸番号1乃至449に記載のアミノ酸配列からなる重鎖及び配列番号2においてアミノ酸番号1乃至214に記載のアミノ酸配列からなる軽鎖を含んでなる抗体、又は、
(2)配列番号1に記載のアミノ酸配列からなる重鎖及び配列番号2に記載のアミノ酸配列からなる軽鎖を含んでなる抗体である。
[抗体-薬物コンジュゲートの製造に使用される薬物リンカー中間体]
本発明に係る抗体-薬物コンジュゲートの製造に使用される薬物リンカー中間体は、次式で示される。
本発明で使用される抗体-薬物コンジュゲートは、前述の薬物リンカー中間体と、チオール基(又はスルフヒドリル基とも言う)を有する抗体を反応させることによって製造することができる。
本発明において「免疫チェックポイント阻害剤」とは、免疫抑制系を阻害し、腫瘍免疫を活性化する薬剤を示す。
以下、本発明に係る抗体-薬物コンジュゲートと免疫チェックポイント阻害剤が組み合わされて投与されることを特徴とする医薬組成物及び治療方法、並びに、本発明に係る抗体-薬物コンジュゲートを含有する、抗腫瘍免疫を活性化する作用により改善される疾患の治療に用いることを特徴とする医薬組成物及び治療方法について説明する。
国際公開第2015/115091号に記載の製造方法に従って、ヒト化抗HER2抗体(トラスツズマブ)を用いて、式
で示される薬物リンカーと、抗HER2抗体とがチオエーテル結合によって結合した抗体-薬物コンジュゲート(以下、「抗体-薬物コンジュゲート(1)」と称する)を製造した。
国際公開第2014/057687号に記載の製造方法に従って、式
マウス:6週齢の雌性BALB/cマウス(BALB/c AnNCrlCrlj)(日本チャールス・リバー社)を実験に供した。
測定、計算式:腫瘍の長径および短径を電子式デジタルキャリパー(CD15-CX、株式会社ミツトヨ)で1週間に2回測定し、腫瘍体積(mm3)を計算した。計算式は以下に示すとおり。
腫瘍体積(mm3)=0.5×長径(mm)×[短径(mm)]2
腫瘍体積が3000 mm3を超えた個体については動物実験倫理の観点から安楽殺を行った。
評価例1と同様に試験を実施した。なお、抗PD-1抗体は、5 mg/kgの用量でDays 0、3、7および10に計4回尾静脈内投与し、各群のマウス匹数は20 匹、Day 38まで腫瘍体積を測定した。コントロール群と抗体-薬物コンジュゲート(1)群及び抗PD-1抗体群の薬効の比較、抗体-薬物コンジュゲート(1)及び抗PD-1抗体群と両剤併用群の薬効の比較をカプランマイヤー法・ログランク検定(多群の比較)を用いて実施した。推定腫瘍体積が3000mm3を超えた日(安楽殺した日)をイベント発生日(死亡日)とした。多重性調整済みのP値は小数点以下4桁で記載し、P<0.05(両側検定)を有意とした。
結果を図4に示す。コントロール群と比較して、抗体-薬物コンジュゲート(1)群は、有意に優れた抗腫瘍効果を示した(P=0.0001)。また、コントロール群と比較して、抗PD-1抗体群は有意に優れた抗腫瘍効果を示した(P=0.0010)。さらに、抗体-薬物コンジュゲート(1)群と比較して、併用群は、有意に優れた抗腫瘍効果を示した(P=0.0006)。また、抗PD-1抗体群と比較して、併用群は、有意に優れた抗腫瘍効果を示した(P<0.0001)。
評価例1と同様に、CT26.WT-hHER2細胞を皮下移植されたマウスに抗体-薬物コンジュゲート(1)を投与した。なお、移植後5日目に無作為群分けを実施した。これらのマウスのうち、腫瘍が完全に消失したマウスを選別した(以下、「抗体-薬物コンジュゲート(1)処置治癒マウス」と称する。)。また、コントロールとして無処置のマウスを用いた(以下、「コントロールマウス」と称する。)。
次に、抗体-薬物コンジュゲート(1)処置治癒マウス、及び、コントロールマウスそれぞれの左腋窩部に5.0×106 cellsのCT26.WT-hHER2細胞、あるいはCT26.WT-mock細胞を皮下移植し(再移植、Day 0)、Day 17まで腫瘍体積を測定した。なお、各群のマウス匹数は9匹とした。
結果を図5に示す。縦軸に腫瘍体積(mm3)、横軸は再移植後からの日数を示している。コントロールマウスにCT26.WT-hHER2細胞、あるいはCT26.WT-mock細胞を再移植した場合は、それぞれ腫瘍の増殖が認められた。一方、抗体-薬物コンジュゲート(1)処置治癒マウスにCT26.WT-hHER2細胞、あるいはCT26.WT-mock細胞を再移植した場合は、いずれも腫瘍の増殖がほとんど認められず、拒絶されることが認められた。以上より、抗体-薬物コンジュゲート(1)投与により、腫瘍に対する免疫記憶が形成されることが確認された。
Murine IFNγ Single-Color Enzymatic ELISPOT Assayを用いて実施した。評価例3で使用したマウスより脾臓を摘出し、脾臓細胞をCTL test mediumを用いて1.0 x 106 cells/mLに調製した。また、CT26.WT-hHER2細胞、及びCT26.WT-mock細胞のそれぞれを、10 μg/mLのマイトマイシンCで2時間処置し、洗浄後、細胞を回収してCTL test mediumを用いて1.0 x 106 cells/mLに調製し、抗原とした。脾臓細胞と抗原を各100μL/wellで抗IFNγ抗体コート済みPVDF-membraneプレートに添加し、24時間、37℃で共培養したのち、IFNγ産生脾臓細胞数を測定した。コントロール群と抗体-薬物コンジュゲート(1)群との比較は、ウィルコクソンの順位和検定にて行い、P値は小数点以下4桁で記載し、P<0.05(両側検定)を有意とした。
結果を図6から9に示す。CT26.WT-hHER2細胞を再移植した抗体-薬物コンジュゲート(1)処置治癒マウスの脾臓細胞は、コントロールマウスの脾臓細胞と比較して、CT26.WT-hHER2細胞由来の抗原によって、有意に多いIFNγ産生脾臓細胞数が確認された(P=0.0012、図6)。また、CT26.WT-mock細胞由来の抗原によっても、有意に多いIFNγ産生脾臓細胞数が確認された(P=0.0008、図7)。
さらに、CT26.WT-mock細胞を再移植した場合においても、抗体-薬物コンジュゲート(1)処置治癒マウスの脾臓細胞は、コントロールマウスの脾臓細胞と比較して、CT26.WT-hHER2細胞由来の抗原によって、有意に多いIFNγ産生脾臓細胞数が確認された(P=0.0116、図8)。また、CT26.WT-mock細胞由来の抗原によっても、有意に多いIFNγ産生脾臓細胞数が確認された(P=0.0052、図9)。
以上の結果から、抗体-薬物コンジュゲート(1)処置治癒マウスにおいて、ヒトHER2以外のCT26.WT細胞由来の抗原を認識するT細胞が誘導されていることが示唆された。
BALB/cマウスを安楽殺後、大腿骨より骨髄細胞を分取し、10% FBS, 55 μM 2-メルカプトエタノール, 100 U/mLペニシリン, 100 U/mLストレプトマイシン, 1 mMピルビン酸ナトリウム, 1 × non-essential amino acid, 2 mM L-グルタミン, 10 ng/mLマウス GM-CSF含有RPMI 1640培地で11日間培養し、骨髄由来樹状細胞を誘導した。誘導した樹状細胞の培養液に、化合物(A)を0.0625 μM, 0.125 μM, 0.25 μM, 0.5 μM, 1 μMで添加した。また、コントロールとしてDMSOを化合物(A)と同量で添加した。24時間後にPacific Blue labeled anti-mouse CD45 Antibody (103126, BioLegend), PE labeled anti-mouse CD86 (B7-2) (553692, Becton Dickinson), APC labeled anti-mouse CD11c (550261, Becton Dickinson), FITC labeled anti-mouse MHC Class II (I-A/I-E) (11-5321-85, Thermo Fisher Scientific)を用いて染色し、FACS Canto IIにて解析を実施した。なお、死細胞はThermo Fisher Scientific社より購入したLIVE/DEAD Fixable Near-IR Dead Cell Stain Kitで染色し、解析から除外した。
評価例1と同様にCT26.WT-hHER2をマウスに移植後、8日後に無作為に群分けを実施した(Day 0)。抗体-薬物コンジュゲート(1)は10 mg/kgの用量でDays 0に尾静脈内投与した。コントロール群として抗体-薬物コンジュゲート(1)の専用溶媒を投与する群を設定した。各群のマウス匹数は7匹とし、Day 8にマウスを安楽殺後、腫瘍を摘出した。Miltenyi Biotec社より購入したTumor Dissociation Kit, mouseを用いて、腫瘍より単細胞懸濁液を調製し、評価例5と同様に染色、解析した。コントロール群と抗体-薬物コンジュゲート(1)群との比較は、スチューデントのt検定にて行い、P値は小数点以下4桁で記載し、P<0.05(両側検定)を有意とした。
腫瘍内のCD45陽性細胞(リンパ球細胞)に占めるCD11c、MHC class II, CD45陽性細胞(樹状細胞、DC)が、抗体-薬物コンジュゲート(1)投与によって有意に増加することが確認された(図12)。
また、CD86(活性化マーカー)を発現している樹状細胞が、抗体-薬物コンジュゲート(1)投与によって有意に増加することが確認された(図13)。
さらに、MFI(mean fluorescence intensity)にて測定した樹状細胞上のCD86の発現量も、抗体-薬物コンジュゲート(1)投与によって有意に増加することが確認された(図14)。
以上の結果より、担癌マウスに抗体-薬物コンジュゲート(1)を投与することにより、腫瘍内リンパ球に占める樹状細胞の数の増加、腫瘍内樹状細胞に占めるCD86陽性細胞の増加、樹状細胞上のCD86の発現量の増加が確認された。
評価例6と同様に細胞懸濁液を調製後、PE labeled anti-human Her2/neu (340552, Becton Dickinson), APC labeled anti-mouse CD274 (B7-H1, PD-L1) (124312, BioLegend), FITC labeled anti-mouse H-2Dd (110606, BioLegend)で染色を実施し、がん細胞上のMHC class Iの発現量、及び、PD-L1の発現量をフローサイトメトリーにて測定した。なお、死細胞はThermo Fisher Scientific社より購入したLIVE/DEAD Fixable Near-IR Dead Cell Stain Kitで染色し、解析から除外した。コントロール群と抗体-薬物コンジュゲート(1)群との比較は、スチューデントのt検定にて行い、P値は小数点以下4桁で記載し、P<0.05(両側検定)を有意とした。
がん細胞(ヒトHER2陽性細胞)上のMHC class Iの発現量が、抗体-薬物コンジュゲート(1)投与により有意に増加することが確認された(図15)。MHC class IはT細胞が、がん細胞を認識する際に必要な分子である。従って、抗体-薬物コンジュゲート(1)はがん細胞上のMHC class Iの発現量の増加を促進することにより、抗腫瘍免疫を活性化していることが示唆された。
また、がん細胞上のPD-L1の発現量も、抗体-薬物コンジュゲート(1)により有意に増加することが確認された(図16)。PD-L1はT細胞上のPD-1に作用して、免疫抑制性のシグナルを入れることで知られている。従って、抗体-薬物コンジュゲート(1)はがん細胞上のPD-L1の発現量の増加を促進することで、抗腫瘍免疫を抑制していることが示唆され、PD-1抗体と併用することでその抑制性シグナルが解除され、より強い抗腫瘍効果を示すと考えられる。
CT26.WT-hHER2細胞の培養液に、化合物(A)を0.0625 μM, 0.125 μM, 0.25 μM, 0.5 μM, 1 μMで添加した。また、コントロールとしてDMSOを化合物(A)と同量で添加した。24時間後にPE labeled anti-human Her2/neu (340552, Becton Dickinson), FITC labeled anti-mouse H-2Dd (110606, BioLegend)で染色を実施し、がん細胞上のMHC class Iの発現量をフローサイトメトリーにて測定した。なお、死細胞はThermo Fisher Scientific社より購入したLIVE/DEAD Fixable Near-IR Dead Cell Stain Kitで染色し、解析から除外した。MHC class Iのmean fluorescence intensity(MFI)を算出し、染色した細胞におけるMFIからIsotype controlで処理した細胞におけるMFIを引いた値をadjusted MFIとした。コントロール群と化合物(A)群との比較は、ダネットの検定にて行い、P値は小数点以下4桁で記載し、P<0.05(両側検定)を有意とした。
結果を図17に示す。
CT26.WT-hHER2細胞上のMHC class Iの発現量が化合物(A)によって有意に増加することが確認された(図17)。従って、化合物(A)は、がん細胞上のMHC class Iの発現量の増加を促進することにより、抗腫瘍免疫を活性化していることが示唆された。
マウス:6週齢の雌性BALB/c-nuマウス(CAnN.Cg-Foxn1[nu]/CrlCrlj〔Foxn1nu/Foxn1nu〕)(日本チャールス・リバー社)を実験に供した。
測定、計算式:腫瘍の長径および短径を電子式デジタルキャリパー(CD15-CX、株式会社ミツトヨ)で1週間に2回測定し、腫瘍体積(mm3)を計算した。計算式は以下に示すとおり。
腫瘍体積(mm3)=0.5×長径(mm)×[短径(mm)]2
腫瘍体積が3000 mm3を超えた個体については動物実験倫理の観点から安楽殺を行った。
CT26.WT-hHER2細胞を生理食塩水に懸濁し、5.0×106 cellsをBALB/c-nuマウスの右腋窩部に皮下移植し、3日後に無作為に群分けを実施した(Day 0)。抗体-薬物コンジュゲート(1)は10 mg/kgの用量でDays 0および7に計2回尾静脈内投与した。コントロール群として抗体-薬物コンジュゲート(1)の溶媒を投与する群を設定した。各群のマウス匹数は12匹とし、Day 13まで腫瘍体積を測定した。
抗体-薬物コンジュゲート(1)投与群、コントロール抗体-薬物コンジュゲート投与群、及びコントロール群について、評価例1と同様の方法で、CT26.WT-hHER2細胞を皮下移植されたマウスにおける、腫瘍体積の推移を測定した。
マウス、ヒト由来の分子以外に結合するヒトIgG1抗体を用いたコントロール抗体-薬物コンジュゲート(Drug-to-Antibody Ratio: 7.8)は専用溶媒によって希釈して使用した。なお、群分けは移植5日後に実施した(Day 0)。コントロール抗体-薬物コンジュゲートおよび抗体-薬物コンジュゲート(1)は10 mg/kgの用量でDays 0および7に計2回尾静脈内投与した。各群のマウス匹数は10匹とし、Day 10まで腫瘍体積を測定した。コントロール抗体-薬物コンジュゲート群と抗体-薬物コンジュゲート(1)群の薬効の比較をウィルコクソンの順位和検定を用いて実施した。P値は小数点以下4桁で記載し、P<0.05(両側検定)を有意とした。
抗体-薬物コンジュゲート(1)及び抗PD-1抗体(clone RMP1-14)それぞれの単剤投与群と併用群について、評価例1と同様の方法で、EMT6-hHER2細胞を皮下移植されたマウスにおける、腫瘍体積の推移を測定した。なお、EMT6-hHER2細胞は、American Type Culture Collection社より購入したマウス乳がん細胞株EMT6(CRL-2755)にレンチウイルスベクターを用いてヒトHER2遺伝子を導入することにより作成した。この細胞は細胞膜上にヒトHER2蛋白を発現している。EMT6-hHER2細胞を生理食塩水に懸濁し、1.0×106 cellsを5週齢のBALB/cマウスの右腋窩部に皮下移植し、移植4日後に無作為に群分けを実施した(Day 0)。抗体-薬物コンジュゲート(1)は10 mg/kgの用量でDay 0に1回尾静脈内投与した。抗PD-1抗体(clone RMP1-14)はD-PBS(-)(WAKO)で調製し、5.0 mg/kgの用量でDays 0、3、7および10に計4回尾静脈内投与した。また抗体-薬物コンジュゲート(1)と抗PD-1抗体の併用投与群およびコントロール群として抗体-薬物コンジュゲート(1)の専用溶媒を投与する群を設定した。各群のマウス匹数は11匹とし、Day 17まで腫瘍体積を測定した。コントロール群と抗体-薬物コンジュゲート(1)群及び抗PD-1抗体群の薬効の比較、抗体-薬物コンジュゲート(1)及び抗PD-1抗体群と両剤併用群の薬効の比較をダネットの検定(多群の比較)を用いて実施した。多重性調整済みのP値は小数点以下4桁で記載し、P<0.05(両側検定)を有意とした。
抗体-薬物コンジュゲート(1)及び抗PD-L1抗体それぞれの単剤投与群と併用群について、評価例1と同様の方法で、CT26.WT-hHER2細胞を皮下移植されたマウスに対する延命効果を測定した。抗PD-L1抗体(clone 10F.9G2)はBio X Cell社から購入し、InVivoPure pH6.5 Dilution Buffer(Bio X Cell社)で希釈して使用した。移植6日後に無作為に群分けを実施し(Day 0)、抗体-薬物コンジュゲート(1)は10 mg/kgの用量でDay 0および7に計2回尾静脈内投与した。抗PD-L1抗体は5 mg/kgの用量でDay 0および3に計2回尾静脈内投与した。また、抗体-薬物コンジュゲート(1)と抗PD-L1抗体の併用投与群およびコントロール群として抗体-薬物コンジュゲート(1)の専用溶媒を投与する群を設定した。各群のマウス匹数は15匹とし、Day 38まで腫瘍体積を測定した。推定腫瘍体積が3000 mm3を超えた日(安楽殺した日)をイベント発生日(死亡日)とし、コントロール群と抗体-薬物コンジュゲート(1)群及び抗PD-L1抗体群の生存時間の比較、抗体-薬物コンジュゲート(1)群及び抗PD-L1抗体群と両剤併用群の生存時間の比較をカプランマイヤー法・ログランク検定(多群の比較)を用いて実施した。多重性調整済みのP値は小数点以下4桁で記載し、P<0.05(両側検定)を有意とした。
評価例11と同様の方法でEMT6-hHER2細胞をマウスに皮下移植し、抗体-薬物コンジュゲート(1)及び抗PD-L1抗体それぞれの単剤投与群と併用群について、評価例12と同様に延命効果を測定した。移植5日後に無作為に群分けを実施し(Day 0)、抗体-薬物コンジュゲート(1)は10 mg/kgの用量でDay 0に1回尾静脈内投与した。抗PD-L1抗体は5 mg/kgの用量でDay 0および3に計2回尾静脈内投与した。また、抗体-薬物コンジュゲート(1)と抗PD-L1抗体の併用投与群およびコントロール群として抗体-薬物コンジュゲート(1)の専用溶媒を投与する群を設定した。各群のマウス匹数は6匹とし、Day 60まで腫瘍体積を測定した。コントロール群と抗体-薬物コンジュゲート(1)群及び抗PD-L1抗体群の生存時間の比較、抗体-薬物コンジュゲート(1)群及び抗PD-L1抗体群と両剤併用群の生存時間の比較をカプランマイヤー法・ログランク検定(多群の比較)を用いて実施した。多重性調整済みのP値は小数点以下4桁で記載し、P<0.05(両側検定)を有意とした。
抗体-薬物コンジュゲート(1)及び抗CD4抗体それぞれの単剤投与群と併用群について、並びに、抗体-薬物コンジュゲート(1)及び抗CD8抗体それぞれの単剤投与群と併用群について、評価例1と同様の方法で、CT26.WT-hHER2細胞を皮下移植されたマウスにおける、腫瘍体積の推移を測定した。抗体-薬物コンジュゲート(1)は10 mg/kg、depletion抗体である抗CD4抗体(Bio X Cell社、clone GK1.5) 及び抗CD8抗体(Bio X Cell社、clone 53.6.7)は投与直前にD-PBS(-)を用いて1 mg/mLに調製し、それぞれマウス対し200 μg/headでday0及び7に尾静脈内投与した。またコントロール群として抗体-薬物コンジュゲート(1)の専用溶媒を投与する群を設定した。なお、群分けは移植後5日目(Day 0)に実施し、Day 11まで腫瘍体積を測定した。
CT26.WT-hHER2細胞を皮下移植されたマウスに、抗体-薬物コンジュゲート(1)を投与した場合における、腫瘍内生細胞に占めるCD8陽性T細胞の割合、腫瘍内CD8陽性T細胞に占めるGranzyme B陽性細胞の割合、腫瘍内生細胞に占めるGranzyme B陽性のCD8陽性T細胞の割合、及び、腫瘍内生細胞に占めるCD4陽性T細胞の割合を、フローサイトメトリーにて測定した。評価例6と同様の方法で細胞懸濁液を調製後、Pacific Blue labeled anti-mouse CD45 antibody (103126, BioLegend), PE labeled anti-mouse CD3e antibody (553064, Becton Dickinson), PerCP/Cy5.5 labeled anti-mouse CD4 antibody (100434, BioLegend), PE-Cy 7 labeled anti-mouse CD8a antibody (552877, Becton Dickinson), Alexa FluorR 647 labeled anti-human/mouse Granzyme B antibody (515405, BioLegend)で染色を実施し、フローサイトメトリーにて測定した。なお、死細胞はThermo Fisher Scientific社より購入したLIVE/DEAD Fixable Near-IR Dead Cell Stain Kitで染色し、解析から除外した。コントロール群と抗体-薬物コンジュゲート(1)群との比較は、スチューデントのt検定にて行い、P値は小数点以下4桁で記載し、P<0.05(両側検定)を有意とした。
従って、抗体-薬物コンジュゲート(1)は腫瘍内CD8陽性T細胞を増加させ、またその活性化を促進することにより、抗腫瘍免疫を活性化していることが示唆された。
CT26.WT-hHER2細胞を皮下移植されたマウスに、抗体-薬物コンジュゲート(1)を投与した場合における、腫瘍内の単位面積当たりのCD8陽性細胞数をIHCにて測定した。評価例6と同様の方法で、コントロールおよび抗体-薬物コンジュゲート(1)を投与し、投与8日後に、マウスを安楽殺した。なお、各群のマウス匹数は5匹とし、その中央値である3匹の腫瘍を摘出、4%パラホルムアルデヒド・リン酸緩衝液に浸潤し、パラフィンブロックを作製した。抗CD8抗体(クローン:4SM16)で染色し、NanoZoomer 2.0-HT(浜松ホトニクス)を用いて標本画像を取り込み、画像解析ソフトTissue Studio3.0(Definiens)にて組織全領域を対象に解析を実施した。
[評価例17:in vitroがん細胞解析]
がん細胞を各種化合物で処置した場合における、MHC class Iの発現量を測定した。評価例8と同様の方法で、化合物(A)、DM1-SMe、DM4-SMe(J. Med. Chem. (2014),57,16,6949-6964)およびMMAE(Molecular Cancer Therapeutics (2011), 10, 9, 1728-1739)を20 nM, 100 nM, 500 nMで添加しがん細胞上のMHC class Iの発現量をフローサイトメトリーにて測定した。なお、実験はTriplicateで実施した。コントロール群と各濃度の薬剤群との比較は、ダネットの検定にて行い、P値は小数点以下4桁で記載し、P<0.05(両側検定)を有意とした(***: P<0.001, **: P<0.01)。
抗体-薬物コンジュゲート(1)及び抗CTLA-4抗体それぞれの単剤投与群と併用群について、評価例11と同様の方法で、EMT6-hHER2細胞を皮下移植されたマウスにおける、腫瘍体積の推移を測定した。抗CTLA-4抗体(clone 9H10)はBio X Cell社から購入し、D-PBS(-)で希釈して使用した。なお、群分けは移植後5日目に実施した(Day 0)。抗体-薬物コンジュゲート(1)は10 mg/kgの用量でDay 0に1回尾静脈内投与した。抗CTLA-4抗体は5.0 mg/kgの用量でDays 0、3および7の計3回尾静脈内投与した。また抗体-薬物コンジュゲート(1)と抗CTLA-4抗体の併用投与群およびコントロール群として抗体-薬物コンジュゲート(1)の専用溶媒を投与する群を設定した。各群のマウス匹数は10匹とし、Day 14まで腫瘍体積を測定した。コントロール群と抗体-薬物コンジュゲート(1)群及び抗CTLA-4抗体群の薬効の比較、抗体-薬物コンジュゲート(1)及び抗CTLA-4抗体群と両剤併用群の薬効の比較をダネットの検定(多群の比較)を用いて実施した。多重性調整済みのP値は小数点以下4桁で記載し、P<0.05(両側検定)を有意とした。
配列番号2:ヒト化抗HER2抗体軽鎖のアミノ酸配列
Claims (92)
- 抗体-薬物コンジュゲートにおける抗体が、抗HER2抗体、抗HER3抗体、抗TROP2抗体、又は抗B7-H3抗体である、請求項1に記載の医薬組成物。
- 抗体-薬物コンジュゲートにおける抗体が、抗HER2抗体である、請求項2に記載の医薬組成物。
- 抗HER2抗体が、配列番号1においてアミノ酸番号1乃至449に記載のアミノ酸配列からなる重鎖及び配列番号2においてアミノ酸番号1乃至214に記載のアミノ酸配列からなる軽鎖を含んでなる抗体である、請求項2又は3に記載の医薬組成物。
- 抗HER2抗体が、配列番号1に記載のアミノ酸配列からなる重鎖及び配列番号2に記載のアミノ酸配列からなる軽鎖を含んでなる抗体である、請求項2又は3に記載の医薬組成物。
- 抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が2から8個の範囲である、請求項1から5のいずれか1項に記載の医薬組成物。
- 抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が7から8個の範囲である、請求項1から5のいずれか1項に記載の医薬組成物。
- 抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が7.5から8個の範囲である、請求項1から5のいずれか1項に記載の医薬組成物。
- 免疫チェックポイント阻害剤が、抗PD-1抗体、抗PD-L1抗体、又は抗CTLA-4抗体である、請求項1から8のいずれか1項に記載の医薬組成物。
- 免疫チェックポイント阻害剤が、抗PD-1抗体である、請求項9に記載の医薬組成物。
- 免疫チェックポイント阻害剤が、抗PD-L1抗体である、請求項9に記載の医薬組成物。
- 免疫チェックポイント阻害剤が、抗CTLA-4抗体である、請求項9に記載の医薬組成物。
- 抗体-薬物コンジュゲートと、免疫チェックポイント阻害剤が、それぞれ別異の製剤に有効成分として含有され、同時に又は異なる時間に投与されることを特徴とする、請求項1から12のいずれか1項に記載の医薬組成物。
- 抗体-薬物コンジュゲートと、免疫チェックポイント阻害剤が、単一の製剤に有効成分として含有され、投与されることを特徴とする、請求項1から12のいずれか1項に記載の医薬組成物。
- がんの治療のための、請求項1から14のいずれか1項に記載の医薬組成物。
- がんが、肺癌、尿路上皮癌、大腸癌、前立腺癌、卵巣癌、膵癌、乳癌、膀胱癌、胃癌、胃食道接合部腺癌、胃腸間質腫瘍、子宮頸癌、食道癌、扁平上皮癌、腹膜癌、肝臓癌、肝細胞癌、子宮内膜癌、子宮癌、唾液腺癌、腎臓癌、外陰部癌、甲状腺癌、陰茎癌、白血病、悪性リンパ腫、形質細胞腫、骨髄腫、神経上皮組織性腫瘍、神経鞘性腫瘍、頭頸部癌、皮膚癌、咽頭癌、胆のう癌、胆管癌、中皮腫、ページェット病、及び肉腫からなる群より選択される少なくとも一つである、請求項15に記載の医薬組成物。
- がんが大腸癌である、請求項16に記載の医薬組成物。
- がんが乳癌である、請求項16に記載の医薬組成物。
- 抗体-薬物コンジュゲートが、抗腫瘍免疫を活性化する作用を有する、請求項1から18のいずれか1項に記載の医薬組成物。
- 抗体-薬物コンジュゲートが、
(1)腫瘍内CD8陽性T細胞の増加を促進する作用、及び、
(2)腫瘍内CD8陽性T細胞を活性化する作用、
からなる群より選択される少なくとも一つの作用を有する、請求項1から19のいずれか1項に記載の医薬組成物。 - 抗体-薬物コンジュゲートが、腫瘍に対する免疫記憶形成を促進する作用を有する、請求項1から20のいずれか1項に記載の医薬組成物。
- 腫瘍が、抗体-薬物コンジュゲートにおける抗体に対する抗原を発現している、請求項21に記載の医薬組成物。
- 腫瘍の一部が、抗体-薬物コンジュゲートにおける抗体に対する抗原を発現していない、請求項21に記載の医薬組成物。
- 抗体-薬物コンジュゲートが、
(1)腫瘍内の樹状細胞数の増加を促進する作用、
(2)樹状細胞を活性化する作用、及び、
(3)がん細胞上のMHC class I発現量の増加を促進する作用、
からなる群より選択される少なくとも一つの作用を有する、請求項1から23のいずれか1項に記載の医薬組成物。 - 抗体-薬物コンジュゲートが、がん細胞上のPD-L1発現量の増加を促進することにより生じた免疫抑制性シグナルを、免疫チェックポイント阻害剤が解除することにより、該抗体-薬物コンジュゲートがより強い抗腫瘍効果を示すことを特徴とする、請求項1から24のいずれか1項に記載の医薬組成物。
- 抗体-薬物コンジュゲートが、
(1)腫瘍内CD8陽性T細胞の増加を促進する作用、及び、
(2)腫瘍内CD8陽性T細胞を活性化する作用、
からなる群より選択される少なくとも一つの作用を有する、請求項26に記載の医薬組成物。 - 抗体-薬物コンジュゲートが、腫瘍に対する免疫記憶形成を促進する作用を有する、請求項26又は27に記載の医薬組成物。
- 腫瘍が、抗体-薬物コンジュゲートにおける抗体に対する抗原を発現している、請求項28に記載の医薬組成物。
- 腫瘍の一部が、抗体-薬物コンジュゲートにおける抗体に対する抗原を発現していない、請求項28に記載の医薬組成物。
- 抗体-薬物コンジュゲートが、
(1)腫瘍内の樹状細胞数の増加を促進する作用、
(2)樹状細胞を活性化する作用、及び、
(3)がん細胞上のMHC class I発現量の増加を促進する作用、
からなる群より選択される少なくとも一つの作用を有する、請求項26から30のいずれか1項に記載の医薬組成物。 - 抗体-薬物コンジュゲートにおける抗体が、抗HER2抗体、抗HER3抗体、抗TROP2抗体、又は抗B7-H3抗体である、請求項26から31のいずれか1項に記載の医薬組成物。
- 抗体-薬物コンジュゲートにおける抗体が、抗HER2抗体である、請求項32に記載の医薬組成物。
- 抗HER2抗体が、配列番号1においてアミノ酸番号1乃至449に記載のアミノ酸配列からなる重鎖及び配列番号2においてアミノ酸番号1乃至214に記載のアミノ酸配列からなる軽鎖を含んでなる抗体である、請求項32又は33に記載の医薬組成物。
- 抗HER2抗体が、配列番号1に記載のアミノ酸配列からなる重鎖及び配列番号2に記載のアミノ酸配列からなる軽鎖を含んでなる抗体である、請求項32又は33に記載の医薬組成物。
- 抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が2から8個の範囲である、請求項26から35のいずれか1項に記載の医薬組成物。
- 抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が7から8個の範囲である、請求項26から35のいずれか1項に記載の医薬組成物。
- 抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が7.5から8個の範囲である、請求項26から35のいずれか1項に記載の医薬組成物。
- 疾患が、肺癌、尿路上皮癌、大腸癌、前立腺癌、卵巣癌、膵癌、乳癌、膀胱癌、胃癌、胃食道接合部腺癌、胃腸間質腫瘍、子宮頸癌、食道癌、扁平上皮癌、腹膜癌、肝臓癌、肝細胞癌、子宮内膜癌、子宮癌、唾液腺癌、腎臓癌、外陰部癌、甲状腺癌、陰茎癌、白血病、悪性リンパ腫、形質細胞腫、骨髄腫、神経上皮組織性腫瘍、神経鞘性腫瘍、頭頸部癌、皮膚癌、咽頭癌、胆のう癌、胆管癌、中皮腫、ページェット病、及び肉腫からなる群より選択される少なくとも一つである、請求項26から38のいずれか1項に記載の医薬組成物。
- 疾患が大腸癌である、請求項39に記載の医薬組成物。
- 疾患が乳癌である、請求項39に記載の医薬組成物。
- 化合物が、
(1)腫瘍内CD8陽性T細胞の増加を促進する作用、及び、
(2)腫瘍内CD8陽性T細胞を活性化する作用、
からなる群より選択される少なくとも一つの作用を有する、請求項42に記載の医薬組成物。 - 化合物が、腫瘍に対する免疫記憶形成を促進する作用を有する、請求項42又は43に記載の医薬組成物。
- 化合物が、
(1)腫瘍内の樹状細胞数の増加を促進する作用、
(2)樹状細胞を活性化する作用、及び、
(3)がん細胞上のMHC class I発現量の増加を促進する作用、
からなる群より選択される少なくとも一つの作用を有する、請求項42から44のいずれか1項に記載の医薬組成物。 - 疾患が、肺癌、尿路上皮癌、大腸癌、前立腺癌、卵巣癌、膵癌、乳癌、膀胱癌、胃癌、胃食道接合部腺癌、胃腸間質腫瘍、子宮頸癌、食道癌、扁平上皮癌、腹膜癌、肝臓癌、肝細胞癌、子宮内膜癌、子宮癌、唾液腺癌、腎臓癌、外陰部癌、甲状腺癌、陰茎癌、白血病、悪性リンパ腫、形質細胞腫、骨髄腫、神経上皮組織性腫瘍、神経鞘性腫瘍、頭頸部癌、皮膚癌、咽頭癌、胆のう癌、胆管癌、中皮腫、ページェット病、及び肉腫からなる群より選択される少なくとも一つである、請求項42から45のいずれか1項に記載の医薬組成物。
- 抗体-薬物コンジュゲートにおける抗体が、抗HER2抗体、抗HER3抗体、抗TROP2抗体、又は抗B7-H3抗体である、請求項47に記載の治療方法。
- 抗体-薬物コンジュゲートにおける抗体が、抗HER2抗体である、請求項48に記載の治療方法。
- 抗HER2抗体が、配列番号1においてアミノ酸番号1乃至449に記載のアミノ酸配列からなる重鎖及び配列番号2においてアミノ酸番号1乃至214に記載のアミノ酸配列からなる軽鎖を含んでなる抗体である、請求項48又は49に記載の治療方法。
- 抗HER2抗体が、配列番号1に記載のアミノ酸配列からなる重鎖及び配列番号2に記載のアミノ酸配列からなる軽鎖を含んでなる抗体である、請求項48又は49に記載の治療方法。
- 抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が2から8個の範囲である、請求項47から51のいずれか1項に記載の治療方法。
- 抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が7から8個の範囲である、請求項47から51のいずれか1項に記載の治療方法。
- 抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が7.5から8個の範囲である、請求項47から51のいずれか1項に記載の治療方法。
- 免疫チェックポイント阻害剤が、抗PD-1抗体、抗PD-L1抗体、又は抗CTLA-4抗体である、請求項47から54のいずれか1項に記載の治療方法。
- 免疫チェックポイント阻害剤が、抗PD-1抗体である、請求項55に記載の治療方法。
- 免疫チェックポイント阻害剤が、抗PD-L1抗体である、請求項55に記載の治療方法。
- 免疫チェックポイント阻害剤が、抗CTLA-4抗体である、請求項55に記載の治療方法。
- 抗体-薬物コンジュゲートと、免疫チェックポイント阻害剤が、それぞれ別異の製剤に有効成分として含有され、同時に又は異なる時間に投与されることを特徴とする、請求項47から58のいずれか1項に記載の治療方法。
- 抗体-薬物コンジュゲートと、免疫チェックポイント阻害剤が、単一の製剤に有効成分として含有され、投与されることを特徴とする、請求項47から58のいずれか1項に記載の治療方法。
- がんの治療のための、請求項47から60のいずれか1項に記載の治療方法。
- がんが、肺癌、尿路上皮癌、大腸癌、前立腺癌、卵巣癌、膵癌、乳癌、膀胱癌、胃癌、胃食道接合部腺癌、胃腸間質腫瘍、子宮頸癌、食道癌、扁平上皮癌、腹膜癌、肝臓癌、肝細胞癌、子宮内膜癌、子宮癌、唾液腺癌、腎臓癌、外陰部癌、甲状腺癌、陰茎癌、白血病、悪性リンパ腫、形質細胞腫、骨髄腫、神経上皮組織性腫瘍、神経鞘性腫瘍、頭頸部癌、皮膚癌、咽頭癌、胆のう癌、胆管癌、中皮腫、ページェット病、及び肉腫からなる群より選択される少なくとも一つである、請求項61に記載の治療方法。
- がんが大腸癌である、請求項62に記載の治療方法。
- がんが乳癌である、請求項62に記載の治療方法。
- 抗体-薬物コンジュゲートが、抗腫瘍免疫を活性化する作用を有する、請求項47から64のいずれか1項に記載の治療方法。
- 抗体-薬物コンジュゲートが、
(1)腫瘍内CD8陽性T細胞の増加を促進する作用、及び、
(2)腫瘍内CD8陽性T細胞を活性化する作用、
からなる群より選択される少なくとも一つの作用を有する、請求項47から65のいずれか1項に記載の治療方法。 - 抗体-薬物コンジュゲートが、腫瘍に対する免疫記憶形成を促進する作用を有する、請求項47から66のいずれか1項に記載の治療方法。
- 腫瘍が、抗体-薬物コンジュゲートにおける抗体に対する抗原を発現している、請求項67に記載の治療方法。
- 腫瘍の一部が、抗体-薬物コンジュゲートにおける抗体に対する抗原を発現していない、請求項67に記載の治療方法。
- 抗体-薬物コンジュゲートが、
(1)腫瘍内の樹状細胞数の増加を促進する作用、
(2)樹状細胞を活性化する作用、及び、
(3)がん細胞上のMHC class I発現量の増加を促進する作用、
からなる群より選択される少なくとも一つの作用を有する、請求項47から69のいずれか1項に記載の治療方法。 - 抗体-薬物コンジュゲートが、がん細胞上のPD-L1発現量の増加を促進することにより生じた免疫抑制性シグナルを、免疫チェックポイント阻害剤が解除することにより、該抗体-薬物コンジュゲートがより強い抗腫瘍効果を示すことを特徴とする、請求項47から70のいずれか1項に記載の治療方法。
- 抗体-薬物コンジュゲートが、
(1)腫瘍内CD8陽性T細胞の増加を促進する作用、及び、
(2)腫瘍内CD8陽性T細胞を活性化する作用、
からなる群より選択される少なくとも一つの作用を有する、請求項72に記載の治療方法。 - 抗体-薬物コンジュゲートが、腫瘍に対する免疫記憶形成を促進する作用を有する、請求項72又は73に記載の治療方法。
- 腫瘍が、抗体-薬物コンジュゲートにおける抗体に対する抗原を発現している、請求項74に記載の治療方法。
- 腫瘍の一部が、抗体-薬物コンジュゲートにおける抗体に対する抗原を発現していない、請求項74に記載の治療方法。
- 抗体-薬物コンジュゲートが、
(1)腫瘍内の樹状細胞数の増加を促進する作用、
(2)樹状細胞を活性化する作用、及び、
(3)がん細胞上のMHC class I発現量の増加を促進する作用、
からなる群より選択される少なくとも一つの作用を有する、請求項72から76のいずれか1項に記載の治療方法。 - 抗体-薬物コンジュゲートにおける抗体が、抗HER2抗体、抗HER3抗体、抗TROP2抗体、又は抗B7-H3抗体である、請求項72から77のいずれか1項に記載の治療方法。
- 抗体-薬物コンジュゲートにおける抗体が、抗HER2抗体である、請求項78に記載の治療方法。
- 抗HER2抗体が、配列番号1においてアミノ酸番号1乃至449に記載のアミノ酸配列からなる重鎖及び配列番号2においてアミノ酸番号1乃至214に記載のアミノ酸配列からなる軽鎖を含んでなる抗体である、請求項78又は79に記載の治療方法。
- 抗HER2抗体が、配列番号1に記載のアミノ酸配列からなる重鎖及び配列番号2に記載のアミノ酸配列からなる軽鎖を含んでなる抗体である、請求項78又は79に記載の治療方法。
- 抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が2から8個の範囲である、請求項72から81のいずれか1項に記載の治療方法。
- 抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が7から8個の範囲である、請求項72から81のいずれか1項に記載の治療方法。
- 抗体-薬物コンジュゲートにおける1抗体あたりの薬物リンカーの平均結合数が7.5から8個の範囲である、請求項72から81のいずれか1項に記載の治療方法。
- 疾患が、肺癌、尿路上皮癌、大腸癌、前立腺癌、卵巣癌、膵癌、乳癌、膀胱癌、胃癌、胃食道接合部腺癌、胃腸間質腫瘍、子宮頸癌、食道癌、扁平上皮癌、腹膜癌、肝臓癌、肝細胞癌、子宮内膜癌、子宮癌、唾液腺癌、腎臓癌、外陰部癌、甲状腺癌、陰茎癌、白血病、悪性リンパ腫、形質細胞腫、骨髄腫、神経上皮組織性腫瘍、神経鞘性腫瘍、頭頸部癌、皮膚癌、咽頭癌、胆のう癌、胆管癌、中皮腫、ページェット病、及び肉腫からなる群より選択される少なくとも一つである、請求項72から84のいずれか1項に記載の治療方法。
- 疾患が大腸癌である、請求項85に記載の治療方法。
- 疾患が乳癌である、請求項85に記載の治療方法。
- 化合物が、
(1)腫瘍内CD8陽性T細胞の増加を促進する作用、及び、
(2)腫瘍内CD8陽性T細胞を活性化する作用、
からなる群より選択される少なくとも一つの作用を有する、請求項88に記載の治療方法。 - 化合物が、腫瘍に対する免疫記憶形成を促進する作用を有する、請求項88又は89に記載の治療方法。
- 化合物が、
(1)腫瘍内の樹状細胞数の増加を促進する作用、
(2)樹状細胞を活性化する作用、及び、
(3)がん細胞上のMHC class I発現量の増加を促進する作用、
からなる群より選択される少なくとも一つの作用を有する、請求項88から90のいずれか1項に記載の治療方法。 - 疾患が、肺癌、尿路上皮癌、大腸癌、前立腺癌、卵巣癌、膵癌、乳癌、膀胱癌、胃癌、胃食道接合部腺癌、胃腸間質腫瘍、子宮頸癌、食道癌、扁平上皮癌、腹膜癌、肝臓癌、肝細胞癌、子宮内膜癌、子宮癌、唾液腺癌、腎臓癌、外陰部癌、甲状腺癌、陰茎癌、白血病、悪性リンパ腫、形質細胞腫、骨髄腫、神経上皮組織性腫瘍、神経鞘性腫瘍、頭頸部癌、皮膚癌、咽頭癌、胆のう癌、胆管癌、中皮腫、ページェット病、及び肉腫からなる群より選択される少なくとも一つである、請求項88から91のいずれか1項に記載の治療方法。
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3046293A CA3046293A1 (en) | 2016-12-12 | 2017-12-11 | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
JP2018556670A JPWO2018110515A1 (ja) | 2016-12-12 | 2017-12-11 | 抗体−薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ |
AU2017377233A AU2017377233A1 (en) | 2016-12-12 | 2017-12-11 | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
BR112019011794-6A BR112019011794A2 (pt) | 2016-12-12 | 2017-12-11 | composição farmacêutica, e, método terapêutico. |
EP17882216.9A EP3552626A4 (en) | 2016-12-12 | 2017-12-11 | ASSOCIATION OF AN ANTIBODY DRUG CONJUGATE AND AN IMMUNE CONTROL POINT INHIBITOR |
US16/467,614 US11273155B2 (en) | 2016-12-12 | 2017-12-11 | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
CN201780076286.3A CN110049779A (zh) | 2016-12-12 | 2017-12-11 | 抗体-药物缀合物和免疫检查点抑制剂的组合 |
KR1020197016311A KR20190095280A (ko) | 2016-12-12 | 2017-12-11 | 항체-약물 콘주게이트와 면역 체크 포인트 저해제의 조합 |
US17/586,177 US20220143009A1 (en) | 2016-12-12 | 2022-01-27 | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
JP2022163719A JP2022191375A (ja) | 2016-12-12 | 2022-10-12 | 抗体-薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016-240442 | 2016-12-12 | ||
JP2016240442 | 2016-12-12 | ||
JP2017-097067 | 2017-05-16 | ||
JP2017097067 | 2017-05-16 | ||
JP2017183149 | 2017-09-25 | ||
JP2017-183149 | 2017-09-25 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/467,614 A-371-Of-International US11273155B2 (en) | 2016-12-12 | 2017-12-11 | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
US17/586,177 Continuation US20220143009A1 (en) | 2016-12-12 | 2022-01-27 | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018110515A1 true WO2018110515A1 (ja) | 2018-06-21 |
Family
ID=62559619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/044426 WO2018110515A1 (ja) | 2016-12-12 | 2017-12-11 | 抗体-薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ |
Country Status (11)
Country | Link |
---|---|
US (2) | US11273155B2 (ja) |
EP (1) | EP3552626A4 (ja) |
JP (2) | JPWO2018110515A1 (ja) |
KR (1) | KR20190095280A (ja) |
CN (1) | CN110049779A (ja) |
AU (1) | AU2017377233A1 (ja) |
BR (1) | BR112019011794A2 (ja) |
CA (1) | CA3046293A1 (ja) |
SG (1) | SG10201912575RA (ja) |
TW (1) | TW201828993A (ja) |
WO (1) | WO2018110515A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019039483A1 (ja) * | 2017-08-23 | 2019-02-28 | 第一三共株式会社 | 抗体-薬物コンジュゲートの製剤及びその凍結乾燥方法 |
US10513558B2 (en) | 2015-07-13 | 2019-12-24 | Cytomx Therapeutics, Inc. | Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof |
CN112512587A (zh) * | 2018-08-06 | 2021-03-16 | 第一三共株式会社 | 抗体药物缀合物和微管蛋白抑制剂的组合 |
US11168144B2 (en) | 2017-06-01 | 2021-11-09 | Cytomx Therapeutics, Inc. | Activatable anti-PDL1 antibodies, and methods of use thereof |
EP3890789A4 (en) * | 2018-12-03 | 2022-12-14 | Fusion Pharmaceuticals Inc. | COMBINATION RADIOIMMUNOCONJUGATE AND CHECKPOINT INHIBITOR THERAPY |
WO2023219072A1 (ja) * | 2022-05-10 | 2023-11-16 | 第一三共株式会社 | 抗体-薬物コンジュゲートと抗SIRPα抗体の組み合わせ |
WO2024023750A1 (en) | 2022-07-28 | 2024-02-01 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and bispecific checkpoint inhibitor |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7210770B2 (ja) | 2019-03-29 | 2023-01-23 | メドイミューン・リミテッド | 化合物及びその複合体 |
CA3142119A1 (en) * | 2019-05-29 | 2020-12-03 | Daiichi Sankyo Company, Limited | Dosage of an antibody-drug conjugate for treating cancer |
IL299085A (en) * | 2020-06-19 | 2023-02-01 | Agensys Inc | Markers for use in cancer treatment methods with antibody drug conjugates (ADC) |
BR112023023398A2 (pt) * | 2021-05-21 | 2024-01-23 | Remegen Co Ltd | Usos de um conjugado anticorpo-droga em combinação com um inibidor de checkpoint imune e de uma quantidade eficaz de conjugado anticorpo-droga e um inibidor de checkpoint imune, método para tratar um paciente com câncer urotelial, e, composição farmacêutica |
WO2024081933A1 (en) * | 2022-10-13 | 2024-04-18 | The Brigham And Women's Hospital, Inc. | Methods and compositions for improving response to immunotherapy |
Citations (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990007861A1 (en) | 1988-12-28 | 1990-07-26 | Protein Design Labs, Inc. | CHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTOR |
US5821337A (en) | 1991-06-14 | 1998-10-13 | Genentech, Inc. | Immunoglobulin variants |
WO1999054342A1 (en) | 1998-04-20 | 1999-10-28 | Pablo Umana | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
WO2000037504A2 (en) | 1998-12-23 | 2000-06-29 | Pfizer Inc. | Human monoclonal antibodies to ctla-4 |
WO2000061739A1 (en) | 1999-04-09 | 2000-10-19 | Kyowa Hakko Kogyo Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
WO2001000245A2 (en) | 1999-06-25 | 2001-01-04 | Genentech, Inc. | HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
WO2001014424A2 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
WO2002031140A1 (fr) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kogyo Co., Ltd. | Cellules produisant des compositions d'anticorps |
WO2003038043A2 (en) | 2001-11-01 | 2003-05-08 | Uab Research Foundation | Combinations of dr5 antibody and other therapeutic agents |
WO2006121168A1 (en) | 2005-05-09 | 2006-11-16 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
WO2007077028A2 (en) | 2005-12-30 | 2007-07-12 | U3 Pharma Ag | Antibodies directed to her-3 and uses thereof |
WO2008100624A2 (en) | 2007-02-16 | 2008-08-21 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
WO2008156712A1 (en) | 2007-06-18 | 2008-12-24 | N. V. Organon | Antibodies to human programmed death receptor pd-1 |
WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
WO2011066389A1 (en) | 2009-11-24 | 2011-06-03 | Medimmmune, Limited | Targeted binding agents against b7-h1 |
WO2013079174A1 (en) | 2011-11-28 | 2013-06-06 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
WO2014057687A1 (ja) | 2012-10-11 | 2014-04-17 | 第一三共株式会社 | 抗体-薬物コンジュゲート |
WO2014061277A1 (ja) | 2012-10-19 | 2014-04-24 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体-薬物コンジュゲート |
WO2015098099A1 (ja) | 2013-12-25 | 2015-07-02 | 第一三共株式会社 | 抗trop2抗体-薬物コンジュゲート |
WO2015115091A1 (ja) | 2014-01-31 | 2015-08-06 | 第一三共株式会社 | 抗her2抗体-薬物コンジュゲート |
WO2015146132A1 (ja) | 2014-03-26 | 2015-10-01 | 第一三共株式会社 | 抗cd98抗体-薬物コンジュゲート |
WO2015155976A1 (ja) | 2014-04-10 | 2015-10-15 | 第一三共株式会社 | 抗her2抗体-薬物コンジュゲート |
WO2015155998A1 (en) | 2014-04-10 | 2015-10-15 | Daiichi Sankyo Company, Limited | Anti-her3 antibody-drug conjugate |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
JP3008226B2 (ja) | 1991-01-16 | 2000-02-14 | 第一製薬株式会社 | 六環性化合物 |
US5658920A (en) | 1991-01-16 | 1997-08-19 | Daiichi Pharmaceutical Co., Ltd. | Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound |
JP3359955B2 (ja) | 1992-07-16 | 2002-12-24 | 第一製薬株式会社 | 抗腫瘍剤 |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US6504029B1 (en) | 1995-04-10 | 2003-01-07 | Daiichi Pharmaceutical Co., Ltd. | Condensed-hexacyclic compounds and a process therefor |
JPH08337584A (ja) | 1995-04-10 | 1996-12-24 | Dai Ichi Seiyaku Co Ltd | 縮合六環式アミノ化合物、これを含有する医薬及びその製法 |
SG50747A1 (en) | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
CA2192725C (en) | 1995-12-28 | 2004-04-20 | Kenji Tsujihara | Camptothecin derivatives |
JPH1095802A (ja) | 1995-12-28 | 1998-04-14 | Tanabe Seiyaku Co Ltd | カンプトテシン誘導体 |
US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
TW527183B (en) | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
TW409058B (en) | 1996-06-06 | 2000-10-21 | Daiichi Seiyaku Co | Method for preparation of a drug complex |
JPH1171280A (ja) | 1997-06-26 | 1999-03-16 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
JPH1192405A (ja) | 1997-09-19 | 1999-04-06 | Dai Ichi Seiyaku Co Ltd | 薬物複合体 |
WO1999061061A1 (fr) | 1998-05-22 | 1999-12-02 | Daiichi Pharmaceutical Co., Ltd. | Composites medicamenteux |
EA003790B1 (ru) | 1998-10-30 | 2003-10-30 | Дайити Фармасьютикал Ко., Лтд. | Соединение сдлс и способ его измерения |
EP1191944A2 (en) | 1999-06-25 | 2002-04-03 | Genentech, Inc. | METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES |
JP2002060351A (ja) | 2000-03-22 | 2002-02-26 | Dai Ichi Seiyaku Co Ltd | 水酸基を有する薬物を含むdds化合物 |
WO2002000734A1 (fr) | 2000-06-29 | 2002-01-03 | Daiichi Pharmaceutical Co., Ltd. | Compose dds et son procede de preparation |
US6815435B2 (en) | 2000-07-13 | 2004-11-09 | Daiichi Pharmaceutical Co., Ltd. | Pharmaceutical compositions containing DDS compounds |
EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
TWI313609B (en) | 2001-08-21 | 2009-08-21 | Mitsubishi Tanabe Pharma Corp | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor |
EP1482972A4 (en) | 2001-11-20 | 2005-11-23 | Seattle Genetics Inc | TREATMENT OF IMMUNOLOGICAL DISORDERS USING ANTI-CD30 ANTIBODIES |
US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
KR101002443B1 (ko) | 2002-03-01 | 2010-12-17 | 이뮤노메딕스, 인코오포레이티드 | Rs7 항체 |
US9745380B2 (en) | 2002-03-01 | 2017-08-29 | Immunomedics, Inc. | RS7 antibodies |
EP1572242B1 (en) | 2002-12-13 | 2014-04-16 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
US20040202666A1 (en) | 2003-01-24 | 2004-10-14 | Immunomedics, Inc. | Anti-cancer anthracycline drug-antibody conjugates |
EP1722797A4 (en) | 2004-02-26 | 2008-03-19 | Inotek Pharmaceuticals Corp | ISOCHINOLINE DERIVATIVES AND METHOD FOR THE APPLICATION THEREOF |
AU2005218642B2 (en) | 2004-03-02 | 2011-04-28 | Seagen Inc. | Partially loaded antibodies and methods of their conjugation |
NZ550934A (en) | 2004-05-19 | 2010-05-28 | Medarex Inc | Chemical linkers and conjugates thereof |
BRPI0510883B8 (pt) | 2004-06-01 | 2021-05-25 | Genentech Inc | composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação |
JP2008507520A (ja) | 2004-07-22 | 2008-03-13 | ジェネンテック・インコーポレーテッド | Her2抗体組成物 |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
EP1817341A2 (en) | 2004-11-29 | 2007-08-15 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
CN102580084B (zh) | 2005-01-21 | 2016-11-23 | 健泰科生物技术公司 | Her抗体的固定剂量给药 |
DE102005009084A1 (de) | 2005-02-28 | 2006-08-31 | Ktb Tumorforschungsgesellschaft Mbh | Proteinbindende Anthrazyklin-Peptid-Derivate und diese enthaltende Arzneimittel |
DE102005009099A1 (de) | 2005-02-28 | 2006-08-31 | Ktb Tumorforschungsgesellschaft Mbh | Proteinbindende Camptothecin-Peptid-Derivate und diese enthaltende Arzneimittel |
US7833979B2 (en) | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
US20080131428A1 (en) | 2006-02-24 | 2008-06-05 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
CN103030696B (zh) | 2006-05-30 | 2016-09-28 | 健泰科生物技术公司 | 抗体和免疫偶联物及其用途 |
ITMI20061473A1 (it) | 2006-07-26 | 2008-01-27 | Indena Spa | Derivati della camptotecina ad attivita antitumorale |
US20100068181A1 (en) | 2006-12-21 | 2010-03-18 | Schering Corporation | Pyrrolo [3, 2-a] pyridine derivatives for inhibiting ksp kinesin activity |
WO2008116219A2 (en) | 2007-03-22 | 2008-09-25 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8h9 |
KR20210100223A (ko) | 2008-04-30 | 2021-08-13 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
EP2277044B1 (en) | 2008-05-13 | 2015-06-17 | Genentech, Inc. | Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry |
WO2010059315A1 (en) | 2008-11-18 | 2010-05-27 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
PL3903829T3 (pl) | 2009-02-13 | 2023-08-14 | Immunomedics, Inc. | Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo |
BR112012001395A2 (pt) | 2009-07-22 | 2019-09-24 | Enzon Pharmaceuticals Inc | metodo para tratar um câncer her2 positivo em um mamifero metodo para aumentar os efetivos de antagonistas do receptor her2 em um mamifero apresentando um cancêr her2 positivo metodo para inibir o crescimento ou proliferação de células her2 positivas em um mamifero |
WO2011021397A1 (ja) | 2009-08-20 | 2011-02-24 | 国立大学法人千葉大学 | コルヒチン誘導体 |
JP2013505944A (ja) | 2009-09-24 | 2013-02-21 | シアトル ジェネティックス, インコーポレイテッド | Dr5リガンド薬物結合体 |
RS56741B1 (sr) | 2009-11-13 | 2018-03-30 | Daiichi Sankyo Europe Gmbh | Materijal i postupci za lečenje ili prevenciju bolesti povezanih sa her-3 |
EP2506881B1 (en) | 2009-12-02 | 2024-03-06 | Immunomedics, Inc. | Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy |
CA2797095A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
KR101624381B1 (ko) | 2010-05-17 | 2016-05-25 | 가부시키가이샤 리부텍쿠 | in vivo 에서 항종양 활성을 갖는 항인간 TROP-2 항체 |
MX2012013100A (es) | 2010-05-18 | 2013-01-22 | Cerulean Pharma Inc | Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades. |
EP2594589A1 (en) | 2010-06-10 | 2013-05-22 | Sapporo Medical University | ANTI-Trop-2 ANTIBODY |
EP2593142B8 (en) | 2010-07-12 | 2018-12-26 | Pfizer Healthcare Ireland | Multifunctional antibody conjugates |
WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
AU2011286407A1 (en) | 2010-08-06 | 2013-02-21 | Amgen | Use of HER3 binding agents in prostate treatment |
WO2012064733A2 (en) | 2010-11-09 | 2012-05-18 | Medimmune, Llc | Antibody scaffold for homogenous conjugation |
US20120121615A1 (en) | 2010-11-17 | 2012-05-17 | Flygare John A | Alaninyl maytansinol antibody conjugates |
SG11201401699WA (en) | 2011-11-11 | 2014-09-26 | Rinat Neuroscience Corp | Antibodies specific for trop-2 and their uses |
US9427464B2 (en) | 2011-11-22 | 2016-08-30 | Chiome Bioscience Inc. | Anti-human TROP-2 antibody having an antitumor activity in vivo |
WO2013087716A2 (de) | 2011-12-14 | 2013-06-20 | Bayer Pharma Aktiengesellschaft | Neue binder-wirkstoff konjugate (adcs) und ihre verwendung |
US20130280282A1 (en) | 2012-04-24 | 2013-10-24 | Daiichi Sankyo Co., Ltd. | Dr5 ligand drug conjugates |
AU2013274078A1 (en) | 2012-06-14 | 2015-01-29 | Ambrx, Inc. | Anti-PSMA antibodies conjugated to nuclear receptor ligand polypeptides |
JP6262768B2 (ja) | 2013-01-03 | 2018-01-17 | セルトリオン, インク. | 抗体−リンカー−薬物結合体、その製造方法およびそれを含む抗癌剤組成物 |
-
2017
- 2017-12-11 EP EP17882216.9A patent/EP3552626A4/en active Pending
- 2017-12-11 WO PCT/JP2017/044426 patent/WO2018110515A1/ja active Application Filing
- 2017-12-11 US US16/467,614 patent/US11273155B2/en active Active
- 2017-12-11 SG SG10201912575RA patent/SG10201912575RA/en unknown
- 2017-12-11 JP JP2018556670A patent/JPWO2018110515A1/ja active Pending
- 2017-12-11 TW TW106143299A patent/TW201828993A/zh unknown
- 2017-12-11 AU AU2017377233A patent/AU2017377233A1/en active Pending
- 2017-12-11 KR KR1020197016311A patent/KR20190095280A/ko not_active Application Discontinuation
- 2017-12-11 CA CA3046293A patent/CA3046293A1/en active Pending
- 2017-12-11 BR BR112019011794-6A patent/BR112019011794A2/pt unknown
- 2017-12-11 CN CN201780076286.3A patent/CN110049779A/zh active Pending
-
2022
- 2022-01-27 US US17/586,177 patent/US20220143009A1/en active Pending
- 2022-10-12 JP JP2022163719A patent/JP2022191375A/ja active Pending
Patent Citations (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990007861A1 (en) | 1988-12-28 | 1990-07-26 | Protein Design Labs, Inc. | CHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTOR |
US5821337A (en) | 1991-06-14 | 1998-10-13 | Genentech, Inc. | Immunoglobulin variants |
WO1999054342A1 (en) | 1998-04-20 | 1999-10-28 | Pablo Umana | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
WO2000037504A2 (en) | 1998-12-23 | 2000-06-29 | Pfizer Inc. | Human monoclonal antibodies to ctla-4 |
WO2000061739A1 (en) | 1999-04-09 | 2000-10-19 | Kyowa Hakko Kogyo Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
WO2001000245A2 (en) | 1999-06-25 | 2001-01-04 | Genentech, Inc. | HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
WO2001014424A2 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
WO2002031140A1 (fr) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kogyo Co., Ltd. | Cellules produisant des compositions d'anticorps |
WO2003038043A2 (en) | 2001-11-01 | 2003-05-08 | Uab Research Foundation | Combinations of dr5 antibody and other therapeutic agents |
WO2006121168A1 (en) | 2005-05-09 | 2006-11-16 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
WO2007077028A2 (en) | 2005-12-30 | 2007-07-12 | U3 Pharma Ag | Antibodies directed to her-3 and uses thereof |
WO2008100624A2 (en) | 2007-02-16 | 2008-08-21 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
WO2008156712A1 (en) | 2007-06-18 | 2008-12-24 | N. V. Organon | Antibodies to human programmed death receptor pd-1 |
WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
WO2011066389A1 (en) | 2009-11-24 | 2011-06-03 | Medimmmune, Limited | Targeted binding agents against b7-h1 |
WO2013079174A1 (en) | 2011-11-28 | 2013-06-06 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
WO2014057687A1 (ja) | 2012-10-11 | 2014-04-17 | 第一三共株式会社 | 抗体-薬物コンジュゲート |
WO2014061277A1 (ja) | 2012-10-19 | 2014-04-24 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体-薬物コンジュゲート |
WO2015098099A1 (ja) | 2013-12-25 | 2015-07-02 | 第一三共株式会社 | 抗trop2抗体-薬物コンジュゲート |
WO2015115091A1 (ja) | 2014-01-31 | 2015-08-06 | 第一三共株式会社 | 抗her2抗体-薬物コンジュゲート |
WO2015146132A1 (ja) | 2014-03-26 | 2015-10-01 | 第一三共株式会社 | 抗cd98抗体-薬物コンジュゲート |
WO2015155976A1 (ja) | 2014-04-10 | 2015-10-15 | 第一三共株式会社 | 抗her2抗体-薬物コンジュゲート |
WO2015155998A1 (en) | 2014-04-10 | 2015-10-15 | Daiichi Sankyo Company, Limited | Anti-her3 antibody-drug conjugate |
Non-Patent Citations (39)
Title |
---|
"Monoclonal Antibodies", 1980, PLENUM PRESS, pages: 365 - 367 |
ALLEY, S. C. ET AL., CURRENT OPINION IN CHEMICAL BIOLOGY, vol. 14, 2010, pages 529 - 537 |
ANALYTICAL BIOCHEMISTRY, vol. 360, 2007, pages 75 - 83 |
ANDERSEN MH. ET AL., JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 126, 2006, pages 32 - 41 |
BIO TECHNIQUES, vol. 28, January 2000 (2000-01-01), pages 162 - 165 |
BRACCI L. ET AL., CELL DEATH DIFFER., vol. 21, 2014, pages 15 - 25 |
CARMEN, S., BRIEFINGS IN FUNCTIONAL GENOMICS AND PROTEOMICS, vol. 1, no. 2, 2002, pages 189 - 203 |
CELL DEATH AND DIFFERENTIATION, vol. 15, 2008, pages 751 - 761 |
CHEN DS. ET AL., IMMUNITY, vol. 39, 2013, pages 1 - 10 |
DAMLE N. K., EXPERT OPIN. BIOL. THER., vol. 4, 2004, pages 1445 - 1452 |
DUCRY, L. ET AL., BIOCONJUGATE CHEM., vol. 21, 2010, pages 5 - 13 |
HERMANSON, G. T: "Bioconjugate Techniques", 1996, ACADEMIC PRESS, pages: 456 - 493 |
HOWARD A. ET AL., J CLIN ONCOL, vol. 29, pages 398 - 405 |
J. MED. CHEM., vol. 57, no. 16, 2014, pages 6949 - 6964 |
JOHN, L. B. ET AL.: "Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene -modified T cells", CLINICAL CANCER RESEARCH, vol. 19, no. 20, 19 July 2013 (2013-07-19), pages 5636 - 5646, XP002737460 * |
JOURNAL OF CHROMATOGRAPHY A, vol. 705, 1995, pages 129 - 134 |
KOHLERMILSTEIN, NATURE, vol. 256, 1975, pages 495 - 497 |
KUROIWA, Y., NUCL. ACIDS RES., vol. 26, 1998, pages 3447 - 3448 |
MENON S. ET AL., CANCERS, vol. 8, 2016, pages 106 |
MOLECULAR BIOLOGY OF THE CELL, vol. 15, December 2004 (2004-12-01), pages 5268 - 5282 |
MOLECULAR CANCER THERAPEUTICS, vol. 10, no. 9, 2011, pages 1728 - 1739 |
MULLER P. ET AL., SCIENCE TRANSLATIONAL MEDICINE, vol. 7, no. 315, 2015, pages 315ra188 |
NATURE, vol. 321, 1986, pages 522 - 525 |
OGITANI Y. ET AL., CANCER SCIENCE, vol. 107, 2016, pages 1039 - 1046 |
OGITANI Y. ET AL., CLINICAL CANCER RESEARCH, vol. 22, no. 20, 15 October 2016 (2016-10-15), pages 5097 - 5108 |
OGITANI Y. ET AL., CLINICAL CANCER RESEARCH, vol. 22, no. 20, 2016, pages 5097 - 5108 |
OGITANI, Y. ET AL.: "DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising anti tumor efficacy with differentiation from T-DM1", CLINICAL CANCER RESEARCH, vol. 22, no. 20, 15 October 2016 (2016-10-15), pages 5097 - 5108, XP055482007 * |
PARDOLL DM., NAT REV CANCER, vol. 12, 2012, pages 252 - 264 |
PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855 |
SENTER P. D. ET AL., NATURE BIOTECHNOLOGY, vol. 30, 2012, pages 631 - 637 |
SIRIWARDENA, D., OPHTHALMOLOGY, vol. 109, no. 3, 2002, pages 427 - 431 |
STAGG, J. ET AL.: "Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti- CD 137 mAb therapy", PNAS, vol. 108, no. 17, 26 April 2011 (2011-04-26), pages 7142 - 7147, XP055079201 * |
TOMIZUKA, K. ET AL., NATURE GENETICS, vol. 16, 1997, pages 133 - 143 |
TOMIZUKA, K., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 722 - 727 |
TOMOMI NAKAYAMA IWATA, ET AL.: "Abstrac n° 1031: DS-8201a, a HER2-targeting antibody-drug conjugate, to elicit immune responses and benefits in combination with an anti-PD-1 antibody", JOURNAL CLINICAL ONCOLOGY, vol. 35, no. 15, May 2017 (2017-05-01), XP055517554, Retrieved from the Internet <URL:http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.1031> [retrieved on 20180131] * |
WOLCHOK JD., CELL, vol. 162, 2015, pages 937 |
WORMSTONE, I. M., INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 43, no. 7, 2002, pages 2301 - 2308 |
YOSHIDA, H.: "Animal Cell Technology:Basic and Applied Aspects", vol. 10, 1999, KLUWER ACADEMIC PUBLISHERS, pages: 69 - 73 |
ZAWLIK, I. ET AL.: "Immune checkpoints in aggressive breast cancer subtypes", NEOPLASMA, vol. 63, no. 5, July 2016 (2016-07-01), pages 768 - 773, XP055497021 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10513558B2 (en) | 2015-07-13 | 2019-12-24 | Cytomx Therapeutics, Inc. | Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof |
US11168144B2 (en) | 2017-06-01 | 2021-11-09 | Cytomx Therapeutics, Inc. | Activatable anti-PDL1 antibodies, and methods of use thereof |
WO2019039483A1 (ja) * | 2017-08-23 | 2019-02-28 | 第一三共株式会社 | 抗体-薬物コンジュゲートの製剤及びその凍結乾燥方法 |
EP3673918A4 (en) * | 2017-08-23 | 2021-05-19 | Daiichi Sankyo Company, Limited | ANTIBODY-DRUG CONJUGATE PREPARATION AND ASSOCIATED LYOPHILIZATION |
CN112512587A (zh) * | 2018-08-06 | 2021-03-16 | 第一三共株式会社 | 抗体药物缀合物和微管蛋白抑制剂的组合 |
EP3834843A4 (en) * | 2018-08-06 | 2022-05-11 | Daiichi Sankyo Company, Limited | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND TUBULIN INHIBITOR |
EP3890789A4 (en) * | 2018-12-03 | 2022-12-14 | Fusion Pharmaceuticals Inc. | COMBINATION RADIOIMMUNOCONJUGATE AND CHECKPOINT INHIBITOR THERAPY |
WO2023219072A1 (ja) * | 2022-05-10 | 2023-11-16 | 第一三共株式会社 | 抗体-薬物コンジュゲートと抗SIRPα抗体の組み合わせ |
WO2024023750A1 (en) | 2022-07-28 | 2024-02-01 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and bispecific checkpoint inhibitor |
Also Published As
Publication number | Publication date |
---|---|
AU2017377233A1 (en) | 2019-06-13 |
EP3552626A1 (en) | 2019-10-16 |
JP2022191375A (ja) | 2022-12-27 |
CN110049779A (zh) | 2019-07-23 |
US20220143009A1 (en) | 2022-05-12 |
KR20190095280A (ko) | 2019-08-14 |
EP3552626A4 (en) | 2020-06-10 |
CA3046293A1 (en) | 2018-06-21 |
US20190314362A1 (en) | 2019-10-17 |
TW201828993A (zh) | 2018-08-16 |
SG10201912575RA (en) | 2020-02-27 |
BR112019011794A2 (pt) | 2019-10-29 |
US11273155B2 (en) | 2022-03-15 |
JPWO2018110515A1 (ja) | 2019-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018110515A1 (ja) | 抗体-薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ | |
JP7204651B2 (ja) | 抗体-薬物コンジュゲートの製剤及びその凍結乾燥方法 | |
JP7458981B2 (ja) | 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ | |
WO2018159582A1 (ja) | 抗her3抗体-薬物コンジュゲート投与によるegfr-tki抵抗性の非小細胞肺癌の治療方法 | |
US20210290777A1 (en) | Treatment of metastatic brain tumor by administration of antibody-drug conjugate | |
US20230414778A1 (en) | COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPalpha ANTIBODY | |
JP2023554422A (ja) | がんの治療のための多重特異性抗体 | |
KR20230041023A (ko) | 항체-약물 콘주게이트의 제조 방법 | |
WO2021079958A1 (ja) | 抗garp抗体と免疫調節剤の組み合わせ | |
WO2022102695A1 (ja) | 抗b7-h3抗体-薬物コンジュゲート投与による中皮腫の治療 | |
TW202400650A (zh) | 抗體與cd47抑制劑之組合 | |
JP2024075668A (ja) | 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ | |
KR20240074000A (ko) | 항 her3 항체-약물 콘주게이트 투여에 의한 egfr-tki 저항성의 비소세포 폐암의 치료 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17882216 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2018556670 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20197016311 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3046293 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2017377233 Country of ref document: AU Date of ref document: 20171211 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019011794 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017882216 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 112019011794 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190611 |